Bone Marrow Microenvironmental Control Of Hematopoietic Stem Cell Trafficking by Ferraro, Francesca
 
 
UNIVERSITA’ DEGLI STUDI DI PARMA 
 













BONE MARROW MICROENVIRONMENTAL 











Chiar.mo Prof. Enrico Maria Silini 
 
Tutor: 













The	  pathophysiology	  of	  diabetes	  mellitus	  
Diabetes	  Mellitus:	  Progression,	  Forms	  and	  Causes.	  	  Diabetes	   mellitus	   (DM)	   is	   a	   chronic	   incurable	   disease	   that	   disrupts	   the	  physiological	  balancing	  of	  blood	   sugar	  metabolism	  and	   leads	   to	  acute	  and	  chronic	  complications	  that	  yield	  high	  morbidity	  and	  mortality.	  The	  incidence	  and	  prevalence	  of	   diabetes	  worldwide	   has	   reached	   an	   alarming	   proportion.	   Based	   on	   a	   survey	   of	  199	   countries,	   it	   has	   been	   estimated	   that	   the	   number	   of	   adults	  with	   diabetes	   has	  doubled	  within	   the	  past	   three	  decades	   from	  153	  million	   in	  1980	   to	  347	  million	   in	  2008.	   Although	   70%	   of	   the	   observed	   increase	   is	   attributed	   to	   population	   growth	  and	  ageing,	  the	  number	  also	  reflects	  the	  unfortunate	  global	  shift	  towards	  a	  western	  lifestyle	  of	  unhealthy	  diet	  and	  physical	  inactivity	  resulting	  in	  increased	  obesity	  1.	  
There	   are	   two	   types	   of	   diabetes,	   classified	   as	   type	   1	   and	   type	   2	   diabetes,	  which	   also	  have	  multiple	   sub-­‐types	   2.	   Type	  1	   is	   an	   immune-­‐mediated	   form	  where	  abnormal	   antibodies	   attack	   and	   damage	   Langerhans	   cells,	   which	   are	   the	   site	   of	  insulin	   production	   in	   the	   endocrine	   portion	   of	   the	   pancreas.	   Unfortunately,	   the	  specific	   antibody	   or	   the	   triggering	   event	   initiating	   the	   autoimmune	   process	  underlying	  many	  cases	  of	  type	  I	  diabetes	  often	  remains	  unknown	  2.	  
Type	  2	  diabetes,	  which	  is	  the	  most	  common	  form	  of	  diabetes	  accounting	  for	  >90	  percent	  of	  diabetic	   cases,	   is	   associated	  with	   two	  physiological	  defects:	   insulin	  resistance	   in	   the	   insulin-­‐targeted	   peripheral	   tissues	   (adipose	   tissue,	   muscle	   and	  
liver)	  and	   impaired	   insulin	  secretion.	  The	   type	   II	  disease	  evolves	  over	  many	  years	  and	  progresses	  through	  multiple	  stages.	  	  
Although	  there	  is	  some	  controversy	  about	  the	  precise	  sequence	  of	  events	  in	  the	   natural	   history	   of	   type	   2	   diabetes,	   the	   development	   of	   peripheral	   insulin	  resistance	   is	   typically	   an	   early	   event.	   To	   compensate	   for	   insulin	   resistance,	  pancreatic	   beta	   cells	   begin	   to	   increase	   insulin	   production,	   which	   causes	   plasma	  insulin	  levels	  to	  rise.	  However,	  because	  the	  compensation	  may	  not	  be	  complete	  the	  patient	  may	  develop	  impaired	  glucose	  tolerance	  and/or	  impaired	  fasting	  glucose.	  As	  the	  disease	  evolves,	  there	  is	  a	  progressive	  impairment	  in	  the	  ability	  of	  the	  beta	  cell	  to	   secrete	   insulin.	   The	   onset	   of	   overt	   diabetes	   begins	   when	   impaired	   beta	   cell	  function	   exceeds	   the	   ability	   to	   compensate	   for	   the	   preexisting	   insulin	   resistance.	  Once	   insulin	   resistance	   is	   complete,	   the	  magnitude	   of	   hepatic	   glucose	   production	  elevates	   fasting	   plasma	   glucose	   levels	   resulting	   in	   severe	   hyperglycemia	   and	  decompensated	  diabetes.	  	  
Although	   the	  primary	   (genetic)	   causes	  of	   insulin	   resistance	   are	  not	   known,	  much	   is	   known	   about	   some	   factors	   that	   contribute	   to	   the	   pathogenesis	   of	   insulin	  resistance.	   Most	   patients	   with	   type	   2	   diabetes	   are	   obese,	   and	   the	   increase	   in	  adiposity	  is	  believed	  to	  be	  an	  important	  causal	  factor	  in	  the	  development	  of	  insulin	  resistance.	  The	   increase	   in	  adipose	   tissue	   is	  associated	  with	  an	   increase	   in	  plasma	  free	   fatty	   acid	   levels,	   which	   promotes	   hepatic	   glucose	   production	   and	   inhibits	  peripheral	  glucose	  utilization.	  In	  addition,	  the	  diabetic	  state	  leads	  to	  a	  vicious	  cycle	  in	   which	   insulin	   deficiency	   and	   hyperglycemia	   both	   exacerbate	   insulin	   resistance	  
and	   further	   impair	   insulin	   secretion	   3.	   Impaired	   glucose	   tolerance	   (IGT)	   defines	   a	  pre-­‐diabetic	  state	  of	  high	  glucose	   level	   that	  does	  not	  meet	  the	  criteria	   for	  diabetes	  diagnosis	   but	   it	   is	   associated	   with	   insulin	   resistance	   and	   increased	   risk	   of	  cardiovascular	  pathology.	  IGT	  may	  precede	  type	  2	  diabetes	  mellitus	  by	  many	  years.	  Other	   rare	   causes	   of	   diabetes	   accounts	   for	   the	   remaining	   1-­‐2%	   of	   all	   diabetes.	  Briefly,	   in	   MODY	   or	   "Maturity	   onset	   diabetes	   of	   the	   young"	   specific	   genetic	  mutations	   have	   been	   identified.	   The	   most	   common	   is	   mutation	   of	   HFN	   on	  chromosome	   12,	   followed	   by	   mutation	   of	   glucokinase	   (a	   sensor	   for	   glucose)	   in	  chromosome	   7.	   "Latent	   autoimmune	   diabetes	   of	   the	   adult"	   (LADA)	   is	   a	   form	   of	  diabetes	   where	   inflammation	   of	   the	   pancreatic	   islet	   causes	   abnormal	   pancreatic	  beta	  cell	  activity.	  Diabetes	  can	  also	  be	  caused	  by	  any	  pathologic	  process	  that	  leads	  to	  pancreas	  disruption	   (chronic	  pancreatitis,	   cancer,	  hemochromatosis	  etc),	  by	  drugs	  (.i.e.	  corticosteroids)	  and	  viral	  infection	  or	  be	  part	  of	  rare	  genetic	  syndrome	  3.	  
Regardless	   of	   the	   underlying	   cause	   the	   evolution	   and	   the	   development	   of	  diabetes	   and	   related	   complications	   appears	   to	   be	   solely	   due	   poorly	   controlled	  hyperglycemia	  and	  its	  metabolic	  consequences.	  That	  is	  why	  so	  far,	  given	  the	  lack	  of	  a	  pathogenetic	  cure,	   the	  treatment	   for	  diabetes	   focuses	  of	  properly	  controlling	  the	  glycemic	  index,	  which	  is	  often	  very	  difficult	  to	  obtain4.	  	  	  
The	  Pathophysiology	  of	  Diabetes	  Mellitus	  	  DM	  is	  a	  systemic	  disease	  that	  is	  associated	  with	  a	  significantly	  reduced	  quality	  of	  life	  due	   to	   end	   stage	   multi	   organ	   dysfunction	   such	   as	   nephropathy,	   generalized	  microangiopathy	   and	   macroangiopathy	   with	   atherosclerosis,	   retinopathy	   and	  
neuropathy	  2.	  As	  mentioned,	  these	  complications	  have	  been	  traditionally	  attributed	  to	  the	  toxic	  effect	  of	  chronic	  high	  glucose	  levels	  on	  tissue	  parenchymal	  cells.	  These	  elevated	   glucose	   levels	   cause	   non-­‐enzymatic	   glycosylation	   of	   proteins	   with	  production	  of	  advanced	  glycation	  end-­‐products	  (AGEs)	  and	  subsequent	  changes	   in	  their	  solubility	  and	  functions).	  	  This	  seems	  to	  be	  mediated	  by	  the	  high	  concentration	  of	   reactive	   oxygen	   species	   (ROS)	   induced	   by	   the	   overflowing	   mitochondrial	  respiratory	   chain5.	   This	   increased	   production	   of	   ROS	   leads	   to	   the	   activation	   of	  damage-­‐related	   signal	   transduction	   pathways	   that	   induce	   profound	   changes	   in	  vascular	  endothelial	  and	  smooth	  muscle	  cells	  and	  subsequent	  modifications	  of	   the	  extracellular	  matrix	  (ECM).	  	  Consequently,	   DM	   patients	   have	   a	   2-­‐3-­‐fold	   higher	   risk	   of	   developing	  cardiovascular	   disease	   (CVD),	   owing	   to	   the	   widespread	   endothelial	   dysfunction,	  which	   is	   considered	   the	   first	   step	   in	   the	   atherogenetic	   process	   6,7.	   Atherosclerotic	  vascular	  disease	  in	  DM	  is	  aggressive,	  multifocal,	  distal	  and	  develops	  earlier	  than	  in	  non-­‐DM	  subjects.	  Microvascular	  complications,	  including	  retinopathy,	  nephropathy,	  and	  neuropathy,	  develop	  as	  a	   consequence	  of	   structural	  and	   functional	  damage	   to	  the	   microcirculation	   of	   target	   organs.	   Typical	   morphological	   features	   include	  thickening	   of	   the	   basement	   membrane,	   loss	   of	   pericyte	   coverage,	   capillary	  rarefaction,	  excess	  deposition	  of	  stiff	  EMC	  components	  leading	  to	  reduced	  perfusion,	  atrophic	   changes,	   and	   fibrosis	   7.	   All	   these	  morphological	   features	   are	   reflected	   by	  organ	  dysfunctions,	   including	  visual	   loss,	   impaired	  glomerular	   filtration	  or	   tubular	  resorption,	  reduced	  nerve	  conduction	  velocity.	  	  
	  	  
Diabetes	  Mellitus	  and	  the	  Hematopoietic	  System	  
The	  hematopoietic	  system	  or	  blood	  system	  is	  also	  an	  organ	  that	  is	  negatively	  impacted	  by	  DM,	  however,	  the	  effect	  of	  DM	  on	  the	  blood	  has	  been	  relatively	  under	  investigated.	   Interestingly,	   nerves,	   vessels,	   ECM,	   all	   of	   which	   are	   damaged	   in	   DM	  patients,	   are	   also	   components	   of	   the	   bone	   marrow	   microenvironment	   or	   “niche”	  that	   are	   critical	   for	  maintaining	   proper	   hematopoiesis8.	  More	   recent	   observations	  have	   advanced	   the	   idea	   that	   diabetes	   alters	   the	   number,	   function	   and	  motility	   of	  hematopoietic	   stem	  cells	   (HSCs)	   9-­‐11and	   causes	  BM	  neuropathy12.	  Moreover,	   given	  that	   various	   hematopoietic	   cell	   population	   participate	   in	   organ	   repair,	   the	  hypothesis	  that	  diabetes-­‐related	  damage	  to	  the	  bone	  marrow	  and	  HSCs	  perpetuates	  the	   wide-­‐spread	   organ	   damage	   found	   in	   DM	   patients	   has	   emerged.	   This	   notion	  potentially	  unveils	  new	  and	  intriguing	  therapeutic	  perspectives	  for	  prevent	  diabetic	  complications	   other	   than	   tight	   glycemic	   control.	   Therefore,	   understanding	  
precisely	   how	   diabetes	   affects	   the	   physiology	   of	   the	   bone	   marrow	  
microenvironment	   and	   hematopoietic	   stem	   cell	   activity	   will	   provide	  
significant	   insight	   into	   the	   physiopathology	   and	   progression	   of	   diabetes	   as	  
well	  as	  open	  new	  avenues	  for	  developing	  novel	  anti-­diabetic	  therapies.	  	  
To	  clarify	  the	  features	  and	  mechanisms	  driving	  BM	  pathology	  in	  diabetes,	  we	  present	  the	  existing	  data	  of	  how	  complex	  cellular	  networks	  that	  comprise	  the	  bone	  marrow	  microenvironment	  orchestrate	  HSC	  function,	  survival	  and	  trafficking.	  
	  
	  
Hematopoietic	  system	  and	  hematopoiesis	  
The	  mammalian	  hematopoietic	  system	  or	  simply	  ‘the	  blood’	  is	  a	  dynamic	  and	  versatile	  organ	  system	  that	  is	  comprised	  of	  a	  network	  of	  specialized	  cell	  types	  that	  regulate	   physiological	   functions	   such	   as	   systemic	   oxygen	   delivery,	  wound	   healing	  and	  defense	   against	   external	   and	   internal	   pathogens.	   This	   diverse	   network	   of	   cell	  populations	   are	   maintained	   by	   and	   originate	   from	   a	   population	   of	   multi-­‐potent	  somatic	  stem	  cells	  called	  hematopoietic	  stem	  cells	  (HSCs).	  
In	  order	   for	  HSCs	   to	  maintain	  homeostasis	  of	   the	  hematopoietic	   system	   for	  the	   entire	   lifespan	   of	   an	   organism	   and	   they	   carefully	   balance	   decisions	   between	  differentiation	   (commitment)	   towards	   mature	   blood	   cell	   production	   and	   self-­‐duplication	   (self-­renewal)	   processes	   to	   replenish	   and	   maintain	   the	   HSC	   pool.	  Perturbations	   in	   HSC	   biology	   can	   impair	   basic	   physiological	   functions	   such	   as	  pathogen	   defense,	   wound	   healing,	   and	   systemic	   oxygen	   delivery,	   as	   well	   as	  contribute	   to	   the	   development	   of	   blood	   cancers13.	   Therefore,	   understanding	   the	  molecular	   cues	   that	   dictate	   HSC	   behavior	   under	   both	   homeostatic	   and	  physiopathological	   conditions	   will	   provide	   a	   foundation	   for	   developing	   novel	  therapeutic	  strategies	  for	  correcting	  disease	  of	  the	  blood.	  	  	  
In	   adult	  mammals,	   hematopoiesis	   predominantly	   occurs	  within	   the	   bone	  marrow,	  which	   is	   situated	   within	   the	   bone	   cavity.	   Here	   HSCs	   reside	   in	   specialized	  compartments	   called	   ‘niches’	   where	   they	   are	   retained	   in	   a	   quiescent	   state	   14.	  Primitive	   HSCs	   divide	   giving	   rise	   to	   progenitor	   cells	   that	   can	   proliferate	   and	  differentiate	  into	  all	  the	  lineages	  of	  blood	  cells	  (Figure	  1).	  	  	  
	   Spontaneous	  or	  induced	  failure	  at	  any	  point	  in	  the	  hematopoietic	  cascade	  can	  lead	  to	  abnormal	  production	  of	  blood	  cell	  lineages	  and	  eventually	  to	  a	  vast	  variety	  of	  hematopoietic	   disorders	   such	   as	   leukemia,	   lymphoma,	   anemia,	   thrombocytopenia.	  	  	  Many	  of	  these	  disorders	  still	  lack	  effective	  pharmacologic	  treatments	  and	  therefore	  often	  yield	  high	  mortality	  rates.	  	  	  
Bone	  marrow	  transplantation	  (BMT)	  is	  a	  form	  of	  regenerative	  medicine	  that	  is	  used	  to	  treat	  a	  wide	  variety	  of	  human	  hematological	  diseases	  and	  disorders	  15-­‐18.	  Prior	   to	   bone	   marrow	   transplant,	   patients	   are	   administered	   radiation	   and/or	  chemotherapy	   (conditioning)	   that	   serve	   to	   ablate	   a	   patient’s	   entire	   hematopoietic	  system,	   both	   healthy	   and	   diseased	   cells.	   Following	   conditioning	   therapy,	   patients	  are	   given	   either	   an	   autologous	   or	   allogeneic	   stem	   cells.	   For	   an	   autologous	  transplant,	   patients	   are	   infused	   with	   their	   own	   healthy	   HSCs	   that	   were	   collected	  prior	   to	   ablative	   conditioning.	   	   Alternatively,	   patients	   that	   receive	   an	   allogeneic	  transplant	  are	  infused	  with	  bone	  marrow	  cells	  taken	  from	  a	  healthy	  donor15.	  
The	  foundation	  of	  transplantation	  therapy	  is	  built	  upon	  the	  principles	  of	  HSC	  trafficking.	  For	  example,	  HSCs	  have	   the	  ability	   to	   travel	  out	   the	  bone	  marrow	   into	  the	   peripheral	   blood,	   a	   process	   referred	   to	   a	   HSC	   mobilization	   and	   vice-­‐versa	  (homing,	   lodgment	   and	   engraftment)19.	   	   This	   ability	   can	   be	   traced	   back	   to	  embryonic	   life	   where	   HSCs	   utilize	   the	   circulatory	   system	   to	   travel	   from	   specific	  embryonic	  and	  extra-­‐embryonic	  sites	  to	  the	  fetal	   liver,	  and	  ultimately	  ending	  their	  developmental	   journey	   in	   the	   bone	  marrow	   (BM)	  where	   they	   carry	   out	   definitive	  lifelong	  hematopoiesis20.	  
The	  emergence	  of	  the	  hematopoietic	  system.	  
	  	   The	   first	   site	   of	   emergence	  of	   definitive	  HSCs	   in	  mammals	   is	   controversial.	  Anatomically,	   the	   earliest	   sign	  of	   hematopoietic	   activity	   in	  both	  humans	   and	  mice	  can	  be	  found	  in	  the	  yolk	  sac	  around	  embryonic	  day	  721-­‐23.	  Definitive	  HSCs	  originate	  at	  E8.5	  from	  an	  intraembryonic	  site	  near	  the	  aorta,	  the	  para-­‐aortic	  splanchnopleura	  (P-­‐Sp)	   that	   becomes	   the	   aorta-­‐gonad-­‐mesonephros	   (AGM)	   region24.	  Other	   authors	  identified	   the	  allantoic	  mesoderm	  of	   the	  placenta,	  an	  extraembryonic	  site	  as	  a	  site	  for	  multipotent	  HSCs	  in	  the	  early	  embryo	  between	  E8.5	  and	  E9.525-­‐27.	  This	  has	  been	  corroborated	   by	   studies	   in	   heartbeat	   deficient	   Ncx1−/-­‐	   embryos,	   which	   do	   not	  survive	  beyond	  E10.5	  due	  to	  the	  absence	  of	  functional	  circulation,	  suggest	  that	  HSCs	  may	   be	   independently	   generated	   in	   the	   placenta28.	   When	   the	   circulatory	   system	  becomes	  operative,	  definitive	  HSCs	  and	  myeloerythroid	  progenitors	  are	  capable	  to	  migrate	   from	   the	   embryonic	   hematopoietic	   sites	   through	   the	   circulation,	   starting	  their	   migratory	   journey	   by	   colonizing	   fetal	   liver	   at	   E10.529.	   	   From	   the	   fetal	   liver,	  HSCs	  migrate	  to	  the	  BM	  and	  definitively	  establish	  their	  home	  shortly	  before	  birth	  at	  day	  E17.5	  30	  However,	  functional	  HSCs	  will	  only	  exit	  the	  fetal	  liver	  and	  migrate	  when	  the	   BM	   environment	   is	   able	   to	   support	   their	   engraftment	   and	   self-­‐renewal.	  	  Mechanisms	   regulating	   trafficking	   of	   HSCs	   before	   birth	   are	   not	   well	   known.	  However,	   none	   of	   the	   knockout	   animals	   deficient	   in	   a	   single	   molecule	   mediating	  adhesion	   events	   of	   HSCs/progenitors	   under	   flow	   during	   fetal	   or	   adult	   life	   (e.g.	  selectins	   and	   α4	   integrins)	   display	   deficits	   in	   fetal	   liver	   colonization,	   suggesting	  redundancy	  of	  adhesion	  mechanisms	  mediating	  embryonic	  HSC	  migration	  31.	  	  
In	  adult	  life,	  a	  small	  number	  of	  HSCs	  continue	  their	  travel	  from	  bone	  marrow	  to	  the	  blood	  and	  back	  for	  reasons	  that	  are	  not	  yet	  clear.	  Circulating	  HSCs	  can	  “home”	  to	  the	  bone	  marrow	  and	  lodge	  into	  specific	  microenvironments	  termed	  the	  “niche”	  that	   allow	   their	   survival,	   and	   regulate	   their	   self-­‐renewal	   and	   proliferation32,33.	  Conversely,	   BM	   HSCs	   egress	   constitutively	   into	   the	   bloodstream	   by	   a	   reverse	  phenomenon.	   As	  we	  mentioned	   above,	   clinical	   HSC	   transplantation	   capitalizes	   on	  this	  natural	  phenomenon	  through	  the	  enforced	  release	  of	  stem	  cells	  (referred	  to	  as	  “mobilization”)	  by	  cytokines,	  such	  as	  G-­‐CSF,	  and/or	  chemotherapy	  to	  facilitate	  their	  collection	  in	  blood	  by	  leukapheresis	  (ref	  stembook).	  This	  point	  is	  exemplified	  by	  the	  fact	   that	   following	   simple	   intravenous	   infusion	   HSCs/progenitors	   are	   be	   able	   to	  “find	  their	  way”	  to	  the	  BM	  niche	  and	  reconstitute	  the	  BM	  hematopoietic	  reservoir.	  These	  therapies	  significantly	  improve	  the	  clinical	  outcome	  of	  patients	  with	  a	  variety	  of	  oncologic	  and	  non-­‐oncologic	  diseases.	  
The	  hematopoietic	  stem	  cell	  niche	  and	  its	  components	  
HSC	   trafficking	   is	   in	   large	   part	   influenced	   by	   the	   bone	   marrow	  microenvironment	   also	   known	   as	   the	   HSC	   niche.	   The	   niche	   concept,	   as	   an	   HSC-­‐regulatong	   entity,	   was	   first	   introduced	   ain	   1978	   by	   Ray	   Schoefield34.	   Since	   this	  seminal	   report	   an	   enormous	   amount	   of	   data	   has	   been	   generated	   to	   precisely	  characterize	   the	  niche	   components	   that	   are	   critical	   to	  maintain	  HSCs	  homeostasis	  and	   trafficking.	   In	   figure	   2	  we	   summarized	   the	   niche	   components	   that	   have	   been	  identified	  and	  characterized	  so	  far.	  Each	  component	  is	  described	  in	  more	  details	  in	  the	  text	  below.	  	  	  
The	  Endosteal	  Hematopoietic	  Niche	  	   Given	   that	   HSCs	   line	   the	   endosteum,	   it	   was	   initially	   proposed	   that	  osteolineage	   cells	   were	   a	   potential	   supportive	   component	   of	   the	   HSC	   niche.	  Intriguingly,	   one	   of	   the	   very	   first	   studies	   describing	   cells	   that	   behaved	   like	  osteogenic-­‐cell	  was	  actually	  seeking	  to	  determine	  why	  hematopoiesis	  was	  located	  in	  the	   bone.	   Tavassoli	   and	   Crosby	   35	   placed	   bone	   marrow	   fragments	   into	   non-­‐bony	  tissues	   to	   see	   if	   the	   addition	   on	   non-­‐hematopoietic	   bone	   cells	   could	   enable	  engraftment	  of	  hematopoietic	  cells	  in	  those	  tissues.	  Hematopoiesis	  occurred	  only	  if	  a	   bony	   ossicle	   with	   microcirculation	   formed.	   	   Within	   the	   bone	   marrow,	   the	  endosteal	   surfaces	   of	   bone	   were	   recognized	   as	   a	   rich	   source	   of	   primitive	  hematopoietic	   cells	   by	   studies	   that	   analyzed	   preserved	   tissue	   at	   progressive	  distances	  from	  the	  endosteum	  36,37.	  
These	   studies	   suggested	   that	   endosteum	   was	   a	   site	   of	   enrichment	   for	  hematopoietic	  stem/progenitor	  cells	  (HSPCs)	  and	  therefore,	  the	  location	  of	  the	  HSC	  niche.	   	   This	   issue	   is	   controversial,	   however.	   A	   number	   of	   histologic	   studies	   have	  indicated	  that	  HSC	  are	  perivascular	  in	  the	  unmanipulated	  mouse	  bone	  marrow38-­‐41.	  Several	   different	   imaging	   approaches	   have	   demonstrated	   that	   HSCs	   localize	   to	  endosteal	   surfaces	   shortly	   after	   transplant,	   while	   more	   mature	   hematopoietic	  progenitor	   cells	   (HPCs)	   localize	   further	   away42-­‐45..	   	   Hematopoietic	   stem	   cells	   that	  were	   closely	   associated	   with	   the	   endosteum	   were	   also	   shown	   to	   have	   a	   greater	  ability	   to	   reconstitute	   hematopoiesis	   in	   lethally	   ablated	   recipient	  mice	   than	   those	  HSCs	  contained	  in	  the	  central	  marrow	  cavity46.	  When	  HSCs	  were	  acquired	  from	  aged	  donors,	   it	  was	   found	   that	   they	   localize	   to	   sites	   further	   away	   from	   the	   endosteum	  
than	  HSCs	  from	  younger	  donors42,	  suggesting	  that	  HSC	  localization	  within	  the	  bone	  may	   be	   a	   mediator	   of	   the	   difference	   in	   HSC	   function	   observed	   with	   the	   aging	  process.	  	  	  
Studies	  by	  Taichman	  and	  colleagues47-­‐49	  demonstrated	  that	  osteolineage	  cells	  produce	  many	  supportive	  growth	   factors	   including	  granulocyte	  colony	  stimulating	  factor	   (G-­‐CSF),	   granulocyte	   macrophage	   colony	   stimulating	   factor	   (GM-­‐CSF),	  interleukin	   1	   (IL-­‐1),	   IL-­‐6,	   and	   transforming	   growth	   factor	   beta	   (TGF-­‐β).	   	   In	   vivo	  genetic	  approaches	  have	  also	  demonstrated	  that	  osteolineage	  cells	  are	  a	  significant	  regulatory	  component	  of	  hematopoiesis50-­‐53.	  Specifically,	  transgenic	  mice	  selectively	  expressing	   a	   constitutively	   active	   PTH/PTHrP	   receptor	   in	   osteolineage	   cells	  enhanced	  HSC	  expansion	  by	  increasing	  the	  expression	  of	  the	  Notch	  ligand,	  Jagged1.	  Notch	  signaling	  regulates	  cell	  fate	  decisions	  including	  HSC	  self-­‐renewal53-­‐55	  thus	  by	  changing	   self-­‐renewal	   versus	   differentiation	   decisions,	   Notch	   can	   increase	   HSC	  number	   without	   differentiation	   or	   increase	   in	   HPC	   or	   mature	   cells54-­‐56.	   	   This	  regulatory	   relationship	   of	   Notch	   ligand	   expression	   by	   osteolineage	   cells	   may	  restricted	  to	  situations	  of	  increased	  PTH/PTHrP	  receptor	  activation,	  as	  subsequent	  studies	  have	   shown	   that	  Notch	   signaling	   is	  not	  mandatory	   for	   the	  maintenance	  of	  adult	  HSC	  function55.	  
	   Within	  the	  endosteal	  niche,	  HSCs	  are	  retained	  through	  a	  variety	  of	  adhesion	  molecule	   interactions,	   many	   of	   which	   appear	   to	   be	   redundant	   systems.	   	   Early	  studies	  exploring	  the	  role	  of	  osteolineage	  cells	   in	  maintaining	  HSCs	  suggested	  that	  N-­‐cadherin	   interactions	   positively	   effected	   HSCs55,	   however	   more	   recent	   studies	  
have	  contradicted	  these	  findings56.	  	  Numerous	  other	  adhesion	  molecules	  have	  been	  implicated	  as	  contributors	  of	  HSC	  and	  HPC	  tethering,	   including,	  but	  not	   limited	  to,	  the	   integrins	   α4β1	   –	   very	   late	   antigen-­‐4	   (VLA-­‐4)57-­‐62,α5β1	   –	   very	   late	   antigen-­‐5	  (VLA-­‐5)63,	   α4β7	   –	   lymphocyte	   Peyer’s	   patch	   adhesion	  molecule-­‐1	   (LPAM-­‐1)64,	   the	  alpha	  6	  integrins	  (Laminins)65,66,	  CD4467,	  E-­‐selectins68-­‐70,	   the	  angiopoietin	  receptor	  tyrosine	   kinase	   with	   immunoglobulin-­‐like	   and	   EGF-­‐like	   domains-­‐2	   (Tie-­‐2)51,	  endolyn	  (CD164)71,	  the	  calcium-­‐sensing	  receptor	  (CaR)72,	  stromal	  derived	  factor-­‐1α	  SDF-­‐1α73,	  and	  osteopontin	  (OPN)74-­‐76.	  OPN	  is	  also	  a	  negative	  regulator	  of	  HSC	  pool	  size	   within	   the	   bone	   marrow	   niche76,	   and	   knockout	   of	   OPN	   in	   mice	   results	   in	  endogenous	   hematopoietic	   mobilization	   to	   the	   periphery	   and	   increases	   the	  mobilization	   response	   to	  G-­‐CSF74.	   	   Recently,	   osteolineage	   cells	  were	   also	   found	   to	  express	   agrin,	  which	  mediates	   cell-­‐cell	   contact	  with	   short	   term	  HSCs	   and	   initiates	  proliferation,	   perhaps	   functioning	   as	   an	   opposing	   signal	   to	   OPN77.	   	   These	   results	  suggest	  that	  OPN,	  a	  target	  for	  modulation	  of	  the	  endosteal	  HSC	  niche,	  and	  that	  agrin	  receptors,	  a	  target	  on	  HSCs,	  may	  serve	  as	  future	  therapeutic	  strategies	  to	  modify	  and	  enhance	  hematopoietic	   transplant	   and	   recovery,	   in	   line	  with	  previously	  described	  strategies	  targeting	  other	  adhesion	  interactions	  in	  the	  niche78-­‐83.	  
	   Up	  to	  this	  point	  the	  focus	  has	  been	  on	  the	  role	  of	  osteolineage	  cells	  and	  their	  associated	  regulation	  of	  hematopoietic	  cells.	  	  However,	  cells	  of	  hematopoietic	  origin	  also	   support	   and	   regulate	   osteolineage	   cells.	   	   For	   example,	   cell-­‐to-­‐cell	   contact	  between	   osteolineage	   cells	   and	   hematopoietic	   progenitor	   cells	   (HPC)	   has	   been	  shown	   to	   be	   important	   for	  HPC	   survival84.	   Using	   an	   in	   vitro	  system,	   Gillette	   et	   al.	  demonstrated	  that	  human	  CD34+	  cells	  (an	  HPC/HSC	  population	  of	  cells)	  co-­‐cultured	  
with	   osteolineage	   cells	   made	   cell-­‐cell	   contact	   and	   exchanged	   a	   portion	   of	   their	  membrane	   with	   the	   osteolineage	   cells,	   creating	   a	   signaling	   endosome85.	   This	  signaling	  endosome	  caused	  osteolineage	  cells	  to	  down-­‐regulate	  Smad	  signaling	  and	  increase	   production	   of	   SDF-­‐1α,	   suggesting	   that	   hematopoietic	   cells	   may	   instruct	  osteolineage	  cells	  to	  create	  a	  more	  habitable	  environment,	  allowing	  them	  to	  directly	  affect	   their	   own	  microenvironment.	   	   These	   results	  may	   suggest	   that	  HSCs	   help	   to	  create	  their	  own	  niches,	  perhaps	  by	  instructing	  neighboring	  stromal	  cells	  to	  produce	  supportive	  factors.	  	  	  
The	  Endosteal	  Niche	  and	  HSPC	  trafficking	  
	   Administration	  of	  G-­‐CSF	  causes	  HSCs	  and	  HPCs	  egress	  (i.e.	  mobilize)	  from	  of	  the	   bone	  marrow	   and	   into	   the	   peripheral	   blood,	  where	   they	   can	   subsequently	   be	  collected	  by	  apheresis	  and	  used	  in	  hematopoietic	  transplantation.	   	  Treatment	  with	  G-­‐CSF	   causes	   significant	   suppression	  of	   osteolineage	   cells86-­‐88,	   causing	   apoptosis89	  	  and	  a	  characteristic	  "flattening"	  of	  osteolineage	  cells88	  suggesting	  that	  osteolineage	  cells	   actively	   participate	   to	   the	   mobilization	   process.	   	   Recently,	   Winkler	   et	   al.86	  reported	   that	   a	   population	   of	   macrophage	   cells,	   characterized	   as	   F4/80+	   Ly-­‐6G+	  CD11b+	  and	   termed	  “osteomacs”89,	   line	   the	  endosteal	   surfaces	  of	  bone	  and	   that	  G-­‐CSF	   treatment	   resulted	   in	   a	   trafficking,	   and	   reduction	   in	   number,	   of	   osteomacs.	  	  Presumably,	   this	   reduction	   in	   osteomacs	   was	   responsible	   for	   the	   attenuation	   of	  function	  of	  osteolineage	   cells.	   	   Confirming	   this	  hypothesis,	  macrophages	  depletion	  using	   either	   the	   Mafia	   transgenic	   mice,	   which	   allows	   for	   inducible	   deletion	   of	  macrophages,	   or	   with	   clodronate-­‐loaded	   liposomes	   (Clo-­‐lip)	   treatment,	   which	  
selectively	  kill	  macrophages,	  results	   in	  significant	  mobilization	  of	  HSC	  and	  HPC.	   	  A	  similar	   report	   from	  Chow	  et	   al.	   also	   demonstrated	   that	   depletion	   of	  macrophages	  with	   Clo-­‐lip	   treatment	   results	   in	   hematopoietic	   mobilization90,	   describing	   a	   Gr-­‐1negative	   F4/80+	   CD115mid	   CD169+	   macrophage	   population	   as	   a	   regulator	   of	  osteolineage	  cells.	  	  Similar	  to	  the	  osteomac	  population,	  the	  authors	  suggest	  that	  the	  CD169+	   macrophages	   express	   a	   soluble,	   yet	   to	   be	   identified,	   factor(s),	   which	  positively	   supports	   niche	   cells.	   	   In	   comparable	   studies	   by	   Christopher	   et	   al.,	   a	  soluble	   factor	   produced	   by	   monocyte/macrophage	   populations	   supported	  osteolineage	   function91,	   suggesting	   that	   manipulation	   of	   monocyte/macrophage	  populations	   or	   the	   factor(s)	   produced	   by	   them	   is	   a	   future	   therapeutic	   strategy	   to	  manipulate	   the	   endosteal	   niche,	   and	   possibly	   suggest	   a	   novel	   strategy	   for	  therapeutically	  manipulating	  bone	  cells.	  
	   Osteoclasts	   are	   also	   monocyte-­‐derived	   cells,	   which	   are	   present	   along	  endosteal	   surfaces	   of	   bone.	   	   Osteoblasts	   and	   osteoclasts	   regulate	   both	   bone	  formation	   and	   bone	   resorption,	   respectively,	   within	   the	   bone	   marrow	   niche,	   and	  pre-­‐osteoclasts	   cause	   retraction	   of	   osteoblasts92,	   theoretically	   creating	   transient	  "holes"	   in	   the	   HSC	   supporting	   endosteal	   niche.	   Given	   that	   treatment	   with	   G-­‐CSF	  causes	   increases	   in	   osteoclast	   number	   and	   activity93-­‐96	   it	   was	   hypothesized	   that	  osteoclasts	   may	   regulate	   the	   endosteal	   niche	   and	   alter	   HSC	   retention	   and	  localization.	  	  In	  line	  with	  this	  notion,	  increasing	  osteoclast	  activity	  by	  administering	  RANK	   ligand	   correlates	   with	   a	   moderate	   increase	   in	   HPC	   mobilization95.	  Correspondingly,	   stress	  models	   such	   as	   bleeding	   or	   LPS	   treatment	   also	   increased	  the	  number	  of	  osteoclasts	   in	   the	  endosteal	  niche	  and	  HPC	   in	   the	  peripheral	  blood,	  
supporting	   a	   role	   for	   osteoclasts	   in	   niche	   regulation.	   	   Kollet	   et	   al.	   suggested	   that	  osteoclast-­‐derived	   proteolytic	   enzymes,	   such	   as	   Cathepsin	   K,	   degraded	   important	  niche	  retention	  molecules,	  thereby	  facilitating	  egress	  of	  HSC	  and	  HPC94.	   	  Follow-­‐up	  studies	   by	   the	   same	   laboratory	   showed	   decreased	   osteoclast	   maturation	   and	  activity	   in	  CD45	  knockout	  mice,	  with	  reduced	  mobilization	   to	  RANK	   ligand	  and	  G-­‐CSF97	  further	  suggesting	  osteoclasts	  are	  important	  in	  the	  regulation	  of	  the	  endosteal	  niche.	   In	   contrast	   to	   these	   studies,	  Takamatsu	  et	   al.	   reported	  earlier	   that	  while	  G-­‐CSF	   treatment	   increased	   osteoclast	   number	   and	   bone	   resorption	   in	   both	   BALB/c	  mice	  and	  humans,	  the	  increase	  in	  osteoclasts	  did	  not	  occur	  until	  10-­‐15	  days	  or	  6-­‐8	  days,	  respectively,	  after	  treatment	  with	  G-­‐CSF93	  whereas	  niche	  clearance	  by	  G-­‐CSF	  is	  typically	   observed	   4	   to	   5	   days	   after	   treatment,	   and	   therefore	   the	   importance	   of	  osteoclasts	  remains	  unclear.	  	  Similarly,	  treatment	  of	  mice	  with	  osteoclast	  inhibiting	  bisphosphonates	  does	  not	  impair	  HSC	  mobilization	  in	  response	  to	  G-­‐CSF	  and	  in	  fact	  increases	   HSC	   egress98.	   	   Intriguingly,	   the	   endosteal	   surface	   of	   bone,	   specifically	  underneath	   resorbing	   osteoclasts,	   there	   is	   a	   significant	   source	   of	   soluble	  extracellular	  calcium	  that	  previous	  studies	  have	  demonstrated	  that	  HSC	  expression	  of	   calcium	   sensing	   receptors	  mediates	   a	   chemoattraction	   to	   soluble	   Ca2+	  72Genetic	  ablation	   of	   the	   calcium	   sensing	   receptor	   in	  mice	   reduces	   HSC	   content	   within	   the	  bone	  marrow	  niche	  and	  increases	  HSC	  numbers	  in	  the	  peripheral	  blood99,100.	  These	  results	   might	   suggest	   that	   the	   bone	   resorbing,	   and	   subsequent	   Ca2+	   releasing	  activity	  of	  osteoclasts,	  may	  be	  involved	  in	  niche	  retention	  	  
Prior	   to	   hematopoietic	   transplant	   patients	   are	   conditioned	   with	  chemotherapeutic	   agents	   and/or	   irradiation	   to	   remove	   resident	   HSCs	   and	   HPCs,	  
which	  is	  essential	  for	  successful	  engraftment	  of	  donor	  HSCs.	  However,	  these	  agents	  also	   affect	   niche	   cells.	   	   A	   recent	   study	   from	   Dominici	   et	   al.	   demonstrated	   that	  following	  a	  lethal	  dose	  of	  irradiation	  megakaryocytes	  migrate	  toward	  the	  endosteal	  surface	  and	   induce	  a	  2-­‐fold	  expansion	   in	  osteolineage	  cells,	  presumably	   increasing	  the	  available	  niches	   for	   subsequent	  HSC	  engraftment101.	  These	  results	  are	   in	  close	  alignment	   with	   other	   studies	   in	   which	   mice	   deficient	   in	   GATA-­‐1	   and	   NF-­‐E2	  transcription	  factors	  had	  significantly	  increased	  megakaryocyte	  production,	  leading	  to	   a	   6-­‐fold	   expansion	   of	   osteolineage	   cells102,	   a	   process	   requiring	   direct	   cell-­‐cell	  contact	   between	   megakaryocytes	   and	   osteolineage	   cells103,104.	   Further	   support	   of	  blood	   cells	   impacting	  bone	  biology	  are	   the	  observations	   that	   excessive	  blood	   loss,	  which	  stresses	  the	  hematopoietic	  system,	  leads	  to	  osteoporosis	  in	  mice105	  and	  that	  splenectomy	  in	  mice	  results	  in	  an	  expansion	  of	  megakaryocytes	  with	  reduced	  GATA-­‐1	   expression	   and	   increased	   bone	   formation106.	   These	   intriguing	   findings	   suggest	  that	   there	   is	   much	   remains	   to	   be	   learned	   about	   the	   bi-­‐directional	   regulatory	  relationship	   between	   blood	   and	   bone.	   Further	   exploration	   of	   these	   is	   clearly	  warranted	   particularly	   since	   there	   is	   a	   substantial	   prevalence	   of	   bone	   disorders	  following	   hematopoietic	   transplantation	   and	   its	   associated	   conditioning	  regimens107-­‐114.	  
Ageing	  and	  Turnover	  of	  the	  Endosteal	  Niche	  
	   The	  endosteal	  surface	  of	  bone,	  as	  described	  earlier,	  is	  a	  dynamic	  tissue	  with	  a	  high	   turnover	   rate	   of	   osteoblasts	   that	   are	   continually	   replenished	   by	   early	  osteogenic	   precursors	   and	   skeletal	   stem	   cells.	   	   Several	   reports,	   using	   in	   vitro	   co-­‐
culture	  studies	  have	  shown	  that	  HSCs	  cultured	  on	  primitive	  osteolineage	  cells	  have	  a	   higher	   reconstituting	   capacity	   than	   those	   cultured	   on	   more	   mature	  osteoblasts115,116,	  suggesting	  that	   the	  maturational	  status	  of	  osteolineage	  cells	  may	  be	  a	  key	  determinate	  of	  HSC	  support.	  	  Indeed,	  several	  studies	  conducted	  in	  vivo	  have	  revealed	  that	  disrupting	  immature	  osteolineage	  cells,	  which	  resemble	  mesenchymal	  stem	   and	   progenitor	   cells117	   withers	   HSC	   maintenance,	   whereas	   ablation	   of	  differentiated-­‐more	   mature	   osteoblasts	   are	   ablated,	   hematopoiesis	   was	  unaffected118-­‐119.	   	  These	   findings	  suggest	   that	   immature	  osteolineage	  cell	  subset	   is	  an	   essential	   component	   of	   the	   HSC	   niche.	   The	   Nestin+	   multipotent-­‐mesenchymal	  stem	   cells	   express	   high	   levels	   of	   hematopoietic-­‐supportive	   molecules,	   suggesting	  that	   this	   cell	   subset	   is	   also	   unique	   constituent	   of	   the	   bone	   marrow	   niche120.	  	  Intriguingly,	  Nestin+	   cells	  were	   found	   to	  wrap	   around	   endothelial	   cells	  within	   the	  bone	  marrow	  near	   the	  endosteum,	  but	  also	   towards	   the	  central	  marrow,	   implying	  that	   an	   alternate	   HSC	   niche	   localization	   exists	   that	   is	   located	   further	   from	   the	  endosteum,	  commonly	  referred	  to	  as	  the	  vascular	  niche.	  
The	  Vascular	  Niche:	  Vascular	  and	  Perivascular	  Cells	  
	   While	   it	   is	   clear	   that	   HSCs	   reside	   and	   thrive	   within	   the	   endosteal	   bone	  marrow	   niche,	   other	   studies	   have	   identified	   the	   perivascular	   region	   as	   an	  alternative	  HSC	   niche120,121,38,40,41.	   The	   dichotomy	   is	   partially	   reconciled	   by	   recent	  finding	  from	  our	  laboratory	  that	  osteoblasts	  are	  perivascular43,	  but	  the	  reverse	  need	  not	  be	  true:	  there	  may	  be	  a	  perivascular	  niche	  that	  is	  not	  located	  near	  osteoblasts.	  Stem	  cell	   localization	   studies	  utilizing	   two-­‐photon	   in	  vivo	   imaging	  have	  uncovered	  
that	   while	   HSCs,	   on	   average,	   are	   near	   the	   endosteum,	   they	   are	   not	   exclusively	  adjacent	   to	   osteolineage	   cells42,46.	   	   Studies	   assessing	   the	   localization	  of	   progenitor	  cells	  that	  also	  display	  the	  signaling	  lymphocyte	  activation	  molecule	  (SLAM;	  CD150+,	  CD48-­‐	   and	   CD244-­‐)	   expression	   pattern,	   which	   are	   highly	   enriched	   for	   HSCs,	   have	  shown	  that	  these	  SLAM	  cells	  are	  adjacent	  to	  bone	  marrow	  sinusoidal	  blood	  vessels	  as	   oppose	   to	   the	   endosteum,	   suggesting	   the	   existence	   of	   a	   “vascular	   niche”	   for	  HSCs121	  	  This	  is	  supported	  by	  the	  observation	  that	  endothelial	  cells,	  very	  similarly	  to	  osteolineage	   cells,	   can	   support	   hematopoiesis	   both	   in	   vitro	   and	   in	   vivo122-­‐125.	   	  We	  have	  also	  described	  small	  endothelial	  microdomains,	  which	  express	  E-­‐selectin	  and	  SDF-­‐1α,	  and	  act	  as	  a	  point	  of	  entry	  for	  HSC	  after	  transplantation126.	  	  Regeneration	  of	  sinusoidal	   endothelial	   cells	   has	   been	   reported	   to	   be	   essential	   for	   hematopoietic	  reconstitution	   following	   myelosuppression127,	   and	   bone	   marrow	   endothelial	   cells	  support	   the	   growth	   and	   expansion	   of	   HSC	   through	   angiocrine	   factors128.	  	  Interestingly,	  similar	   to	  the	  HSC	  cell	   to	  cell	  contact	  with	  osteolineage	  cells	  altering	  the	  endosteal	  niche	  function84,	  Slayton	  et	  al.	  reported	  that	  donor	  hematopoietic	  cells	  migrated	   to	   sites	   of	   vascular	   sinusoidal	   injury	   within	   bones	   and	   contributed	   to	  repair	   following	   transplantation129,	   further	   highlighting	   the	   complexity	   and	  interconnectedness	  of	  the	  bone	  marrow	  microenvironment130	  
	   While	   it	   is	   not	   completely	   clear	  what	   factors	   influence	   the	   particular	   niche	  location	   of	   HSCs,	   the	   fact	   that	   reticular	   cells	   with	   high	   production	   of	   SDF-­‐1α	   are	  present	   in	   both	   the	   endosteal	   and	   vascular	   niches,	   may	   provide	   a	   common	  mechanism	  of	  HSC	  support	  in	  both	  niches125.	  	  A	  recent	  report	  has	  demonstrated	  that	  shortly	  after	   transplantation	   into	  non-­‐myeloablated	  recipients,	  HSCs	  preferentially	  
localize	  to	  the	  endosteum	  in	  metaphyseal	  regions	  of	  bone	  in	  close	  association	  with	  blood	  vessels131.	   	  Given	   that	   the	  endosteal	   region	   is	   itself	  highly	  vascularized	  may	  suggest	   that	   the	   HSC	   niche	   actually	   encompasses	   overlapping	   regions	   within	   the	  bone.	  	  
Nervous	  System	  Mediators	  of	  the	  HSC	  Niche	  
	   While	   it	   is	   clear	   that	   cellular	   and	   molecular	   constituents	   within	   the	  microenvironment	   interact	   and	   co-­‐regulate	   each	   other,	   the	   question	   arises	   as	   to	  whether	  there	   is	  a	  global	  regulator	  of	   the	  entire	  bone	  system,	  able	  to	  rapidly	  alter	  numerous	  components	  of	   the	  niche	  to	  respond	  as	  needed.	   	  The	  recently	  described	  nestin+	  MSCs	   are	   highly	   intriguing,	   as	   nestin,	   an	   intermediate	   filament	   protein,	   is	  normally	   restricted	   to	   nerve	   cells.	   	   Interstingly,	   the	   same	   laboratory	   has	   also	  demonstrated	   that	   HSC	   and	   HPC	   mobilization	   by	   G-­‐CSF	   requires	   peripheral	   β2-­‐adrenergic	   signals88.	   Specifically,	   the	   authors	   found	   that	   blocking	   β2-­‐adrenergic	  signaling	   in	   mice	   by	   chemical	   sympathectomy	   (using	   6-­‐hydroxydopamine)	   or	  administering	   the	   β-­‐blocker	   propanolol	   or	   genetically	   ablating	   dopamine	   β-­‐hydroxylase	   (Dbh),	   an	   enzyme	   that	   converts	   dopamine	   into	   norepinephrine,	  diminished	  the	  ability	  of	  G-­‐CSF	  to	  induce	  HSC	  mobilaization.	  Moreover,	  the	  authors	  were	  able	  to	  reverse	  the	  Dbh	  knockout	  phenotype	  by	  treating	  mice	  mice	  with	  the	  β2-­‐adrenergic	   agonist,	   Clenbuterol88.	   	   Circadian	   rhythms	   also	   regulate	   HSC	   niche	  retention132,133.	   	   Specifically,	   pharmacological	   inhibition	   of	   β3-­‐adrenergic	   signaling	  disrupts	   rhythmic	   oscillations,	   which	   then	   lead	   to	   uncontrolled	   norepinephrine	  release,	   increased	   CXCR4	   expression,	   and	   enhanced	   SDF-­‐1α	   production	   and	  
therefore	   causing	   regular	   transient	   trafficking	   from	   the	   bone	   marrow	   niche.	  	  Nervous	  system	  signaling	  has	  also	  been	  demonstrated	  to	  have	  direct	  effects	  on	  HSC,	  as	  human	  CD34+	  hematopoietic	  cells	  express	  β2-­‐adrenergic	  and	  dopamine	  receptors	  and	  neurotransmitters,	  such	  as	  norepinephrine,	  serve	  as	  direct	  chemoattractants	  for	  HSCs134,	   underscoring	   the	   global	   control	   the	   nervous	   system	   has	   over	   the	  hematopoietic	  ecologic	  system.	  	  A	  recent	  report	  showed	  that	  β2-­‐adrenergic	  signaling	  causes	  up-­‐regulation	  of	  the	  vitamin	  D	  receptor	  (VDR)	  on	  osteolineage	  cells	  and	  that	  VDR	  signaling	  was	  necessary	  for	  osteolineage	  responses	  to	  G-­‐CSF	  treatment135.	  	  VDR	  expression	   is	   also	   regulated	   by	   circadian	   rhythms136	   providing	   a	   possible	  interconnection	   between	   the	   nervous	   system	   and	   the	   bone	   microenvironmental	  system.	  
	  	   Recently,	  Yamazaki	  et	  al.	  described	  a	  population	  of	  non-­‐myelinating	  Schwann	  cells	  which	   ensheath	   sympathetic	   nerves	   in	   the	   bone	  marrow137.	   	   These	   cells	   are	  primary	  producers	  of	  TGF-­‐β,	  which	  promotes	  HSC	  quiescence138,139,	   and	   therefore	  when	  the	  bone	  is	  denervated,	  the	  loss	  of	  TGF-­‐β	  signaling	  correlates	  with	  a	  reduction	  in	   the	   HSC	   pool137.	   	   Given	   that	   TGF-­‐β	   is	   also	   capable	   of	   attracting	   skeletal	   stem	  cells140,	  this	  may	  suggest	  that	  the	  nervous	  system	  can	  coordinate	  skeletal	  stem	  cell	  trafficking	  and	  migration	  to	  sites	  of	  need,	  though	  further	  exploration	  is	  required.	  	  
The	  role	  of	  adipose	  tissue	  in	  the	  HSC	  Niche	  
Recently,	   adipose	   tissue	   was	   also	   identified	   as	   an	   important	   mediator	   of	  hematopoiesis.	   Adipose,	   or	   “yellow	   marrow”	   is	   a	   major	   constituent	   of	   the	   bone	  marrow	  niche,	  but	  until	  recently	  was	  thought	  to	  play	  a	  passive	  role	  as	  a	  space-­‐filler	  
in	   the	   bone	   marrow	   cavity.	   By	   quantifying	   and	   characterizing	   the	   properties	   of	  hematopoietic	  progenitors	   from	  distinct	  vertebrae	  that	  differ	   in	  adipocyte	  content,	  Naveiras	  et	  al	  determined	  that	  increased	  niche	  adiposity	  correlates	  to	  decreased	  net	  hematopoietic	   cellularity,	   and	   decreased	   number	   and	   activity	   of	   hematopoietic	  progenitors.	  This	  phenomenon	  was	  subsequently	  examined	   in	  a	   transplant	   setting	  by	   performing	   bone	   marrow	   transplant	   on	   ‘fatless’	   A-­‐ZIP/F1	   mice	   that	   lack	  adipocytes.	  These	  mice	  showed	  significantly	  improved	  engraftment,	  white	  blood	  cell	  recovery,	   and	   donor	   chimerism	   post-­‐transplantation	   relative	   to	   wildtype	  controls141.	  	  
The	   described	   results	   suggest	   that	   suppressing	   adipocyte	   number	   in	   a	  transplant	   setting	   could	   provide	   important	   therapeutic	   benefits	   by	   providing	   a	  better	   environment	   for	   HSC	   engraftment.	   Naveiras	   et	   al	   singled	   out	   PPAR-­‐γ	   as	   a	  putative	   target	   that	   could	   be	   pharmacologically	   recapitulate	   the	   engraftment	  phenotype	   of	   A-­‐ZIP/F1	   mice	   in	   wildtype	   animals.	   PPAR-­‐γ	   is	   a	   member	   of	   the	  Peroxisome	   Proliferator-­‐Activated	   Receptor	   family	   of	   nuclear	   hormone	   receptors	  that	  has	  been	  identified	  as	  a	  tissue-­‐specific	  master	  regulator	  of	  adipogenesis.	  In	  the	  presence	  of	  ligands	  such	  as	  steroids,	  cholesterol	  byproducts,	  and	  fatty	  acids,	  PPAR-­‐γ	  forms	   a	   heterodimer	   with	   Retinoid	   X	   Receptor	   (RXR)	   to	   bind	   to	   DNA	   to	   the	  expression	   of	   regulate	   transcription	   of	   genes	   related	   to	   lipid	   and	   carbohydrate	  metabolism	   and	   initiate	   the	   differentiation	   of	   mesenchymal	   stem	   cells	   (MSCs)	   to	  adipocytes142,143.	   The	   necessity	   of	   PPAR-­‐γ	   for	   adipocyte	   differentiation	   has	   been	  established	   by	   several	   experiments.	   PPAR-­‐γ-­‐/-­‐	  mouse	   ES	   cells	   fail	   to	   differentiate	  into	  adipocytes	  in	  culture,	  while	  normal	  adipogenesis	  can	  be	  rescued	  in	  these	  cells	  
by	   viral	   reinsertion	   of	   the	   PPAR-­‐γ	   gene144.	   Furthermore,	   retroviral	   insertion	   of	  PPAR-­‐γ	   into	   wild	   type	   fibroblasts	   promotes	   differentiation	   into	   adipocytes142,	   an	  effect	   that	   can	   be	   recapitulated	   pharmacologically	   by	   treatment	   with	  thiazolidinediones,	  which	  are	  PPAR-­‐γ	  agonists145.	  	  	  Conditional	  knockout	  of	  PPAR-­‐γ	  in	   cells	   expressing	   the	   adipocyte-­‐specific	   promoter	   aP2	   show	   significant	  morphogenic	  defects	  and	   reduced	  body	  mass	  due	   to	  progressive	   lipodystrophy146.	  Collectively,	   these	   data	   establish	   justification	   for	   targeting	   PPAR-­‐γ	   to	   inhibit	  adipogenesis.	  	  
Interplay	  between	  the	  Adipose	  and	  Endosteal	  niches	  
Adipocytes	  and	  osteoblasts	  are	  both	  descendants	  of	  mesenchymal	  stem	  cells	  (MSCs),	   however,	   the	   rates	   of	   osteogenesis	   and	   adipogenesis	   inversely	   correlate	  during	  development	  and	  aging147-­‐149.	  Specifically,	  histological	  analysis	  of	  individuals	  with	  osteoporosis	  and	  aplastic	  anemia	  reveals	  that	  these	  patients	  display	  increased	  adiposity	   that	   is	   associated	   with	   decreased	   bone	   formation	   and	   impaired	  hematopoiesis150,151.	   Moreover,	   samples	   of	   rat	   bone	  marrow	   stromal	   cell	   cultures	  show	   a	   similar	   inverse	   relationship152.	   These	   observations	   suggest	   that	  adipogenesis	   and	   osteogenesis	   could	   be	   antagonistic	   processes	   that	   are	   inversely	  related	  to	  one	  another.	  According	  to	   this	  model	  MSCs	  go	  through	  a	  developmental	  branchpoint,	   where	   niche-­‐mediated	   cues	   dictate	   whether	   MSCs	   commit	   to	  adipogenesis	  or	  osteogenesis.	  	  
Consistent	  with	  this	  hypothesis,	  several	  observations	  suggest	  that	  PPAR-­‐γ	  is	  a	  critical	  mediator	  of	  MSC	  lineage	  fate	  by	  not	  only	  stimulating	  adipogenesis	  but	  also	  
actively	   suppressing	   osteogenesis	   in	   the	   bone	   marrow	   niche.	   	   This	   notion	   was	  initially	  proposed	  based	  on	  the	  finding	  that	  a	  single	  nucleotide	  polymorphism	  in	  the	  PPAR-­‐γ	  gene	   is	   associated	  with	  decreased	  bone	  mineral	  density153.	   Future	   studies	  showing	  that	  several	  other	  PPAR-­‐γ	  polymorphisms	  are	  associated	  with	  osteoporosis	  strengthened	   this	   relationship154.	   Additionally,	   MSCs	   from	   patients	   with	   aplastic	  anemia	   express	   significantly	   higher	   levels	   of	   PPAR-­‐γ	   compared	   to	   control	  individuals155.	   	   Concurrent	   with	   the	   aforementioned	   decrease	   in	   adipogensis,	  PPARgamma-­‐/-­‐	   embryonic	   stem	   cells	   demonstrate	   enhanced	   osteogenesis	   in	  culture144.	   Furthermore,	   mice	   with	   heterozygous	   (PPAR-­‐γ+/-­‐)	   or	   homozygous	  hypomorphic	   (PPAR-­‐γhyp/hyp)	   mutations	   both	   display	   increased	   osteogenesis	  through	   an	   expansion	   of	   the	   osteoblast	   population	   via	   stromal	   precursors144,156.	  Recent	   in	   vitro	   studies	   of	   human	   osteoblasts	   have	   shown	   that	   TNF-­‐α	   signaling	  stimulates	   bone	   mineralization	   via	   downregulation	   of	   PPAR-­‐γ	   in	   the	   osteoblast	  compartment144.	   Perhaps	   the	   most	   interesting	   finding	   is	   that	   pharmacological	  activation	   of	   PPAR-­‐γ	   with	   thiazolidinediones,	   a	   class	   of	   commonly	   used	   anti-­‐diabetes	   drugs,	   results	   in	   decreased	   bone	   mineral	   density,	   concomitant	   with	   an	  overall	   increase	   in	   adipogenesis154,157-­‐159	   .	   This	   suggests	   that	   prolonged	  pharmacological	  modulation	  of	  PPAR-­‐γ	  alone	  is	  sufficient	  to	  alter	  the	  bone-­‐adipose	  equilibrium,	  though	  it	  is	  not	  clear	  at	  what	  rate.	  Given	  the	  role	  of	  osteoblasts	  in	  HSC	  engraftment	   mentioned	   above	   and	   mobilization	   PPAR-­‐γ	   inhibition,	   on	   an	   acute	  timescale,	  could	  have	  important	  therapeutic	  benefits	  in	  bone	  marrow	  transplant.	  
The	   impact	   of	   Diabetes	   Mellitus	   on	   the	   HSCs	   and	   the	   bone	   marrow	  
microenvironment	  
For	   long	   time,	   the	   status	   of	   BM	   in	   patients	   with	   DM	   has	   been	   often	  overlooked,	  however	  it	  has	  recently	  been	  established	  that	  BM	  HSCs	  of	  diabetic	  mice	  compared	  to	  controls	  display	  elevated	  markers	  of	  oxidative	  stress,	  DNA	  damage	  and	  apoptosis	   Furthermore,	   side	   population	   (SP)	   HSPCs	   are	   mis-­‐localized	   in	   diabetic	  bone	  marrow160.	  In	  humans,	  a	  reduction	  in	  CD34+	  HSCs	  was	  found	  in	  BM	  aspirates	  of	   diabetic	   compared	   to	   non-­‐diabetic	   subjects.	   Extensive	   anatomical,	   histological	  and	  cell	  composition	  analyses	  of	  BM	  from	  non-­‐diabetic	  and	  type	  2	  diabetic	  subjects	  display	  microvascular	   and	  hematopoietic	   cell	   rarefaction	   as	  well	   as	   fat	   deposition	  
161.	  
Many	   of	   the	   known	   cellular	   components	   of	   the	   HSC	   niche	   (endosteal,	  perivascular,	   vascular	   and	   neuro-­‐vascular)	   show	   some	   degree	   of	   disruption	   in	  experimental	  models	   of	   diabetes.	   For	   example,	   it	   has	   been	   reported	   that	   diabetes	  disrupts	   BM	   innervation.	   Specifically,	   a	   reduced	   number	   of	   tyrosine	   hydroxylase	  (TyrOH)-­‐immunoreactive	  nerve	  endings	  was	  detected	   in	  the	  BM	  of	   type	  2	  diabetic	  rats12.	   In	   addition	   to	   microangiopathy,	   neuropathy	   and	   stem	   cell	   rarefaction,	   the	  diabetic	   BM	   is	   characterized	   by	   extensive	   fatty	   infiltration	   (Figure	   3),	   which	   as	  mentioned	   above	   negatively	   impacts	   HSCs	   and	   the	   HSC	   niche.	   Collectively,	   these	  data	   establish	   that	   diabetes	   negatively	   impacts	   the	   bone	   marrow	   micro-­‐environment	   and	   HSC	   biology,	   however	   the	   precise	   physiological	   and	   molecular	  mechanisms	  for	  these	  defects	  remain	  unresolved.	  
The	  central	   thesis	  of	   this	  project	  was	   further	  elucidate	   the	  physiological	  and	  
molecular	  events	  that	  lead	  to	  BM	  dysfunction	  in	  diabetes.	  
RATIONALE	  The	  foundation	  of	  this	  project	  was	  built	  upon	  our	   initial	  observations	  made	  during	   an	   analysis	   of	   a	   caseload	   of	   patients	   treated	   with	   G-­‐CSF	   to	   induce	  hematopoietic	  stem	  cell	  (HSC)	  mobilization	  at	  the	  Parma	  Bone	  Marrow	  Transplant	  Centre	   between	  1st	   January	   2004	   and	  30th	  October	   2008.	  Within	   this	   dataset	  we	  observed	   an	   overall	   mobilization	   failure	   rate	   of	   22.6%	   (14/62),	   defined	   as	   <20	  CD34+	   and	   <3000	   polymorphonuclear	   (PMNs)	   cells/ml;	   <5,000	   leukocytes/ml;	  <50,000	   platelets/ml	   blood	   at	   the	   beginning	   of	   leukapheresis.	   Strikingly,	   within	  these	  data	  we	  found	  that	  of	  the	  14	  patients	  who	  were	  classified	  as	  ‘poor	  mobilizers’,	  7	   (50%)	   had	   been	   previously	   diagnosed	   with	   diabetes	   mellitus	   (DM).	   On	   the	  contrary	   only	   25%	   (12/48)	   of	   ‘good	   or	   sufficient	   mobilizers’	   had	   previously	  diagnosed	   with	   DM.	   The	   observed	   difference	   in	   poor	   versus	   good	   mobilizers	  amongst	   diabetic	   patients	   was	   independent	   of	   age,	   gender	   and	   cycles	   of	   prior	  chemotherapy	  (Figure	  4a).	  	  	  
Moreover,	   of	   the	   48	   patients	   that	   were	   able	   to	   sufficiently	   mobilize,	   the	  number	  of	  CD34+	  cells/kg	  was	  significantly	  lower	  in	  diabetic	  individuals	  compared	  to	   non-­‐diabetic	   individuals	   (p=0.014,	   Figure	   4b).	   Glucose	   levels	   were	   also	  significantly	   higher	   in	   poor	   mobilizers	   (p=0.002,	   Figure	   4c)	   irrespective	   of	   a	   DM	  diagnosis.	  	  
We	   also	   observed	   a	   trend	   of	   slower	   neutrophil	   recovery	   (p=0.146)	   and	  significantly	   reduced	   platelet	   recovery	   (p=0.006)	   in	   diabetic	   patients	   following	  peripheral	  blood	  stem	  cell	  transplantation	  (p=0.146	  and	  0.006	  respectively,	  Figure	  
3d).	   Finally,	   we	   also	   found	   that	   within	   patients	   classified	   as	   ‘poor	   mobilizers’,	  diabetic	   patients	   displayed	   a	   significant	   delay	   in	   both	   neutrophil	   and	   platelet	  recovery	   versus	   non-­‐diabetic	   patients	   (p=0.002	   and	   p=0.003,	   respectively;	   Figure	  3e).	  These	  data	  were	  our	  first	  evidence	  that	  diabetes	  mellitus	  may	  negatively	  impact	  the	  cell	  migratory	  patterns	  of	  hematopoietic	  stem	  and	  progenitor	  cells	  (HSPCs).	  	  
 In	   addition	   to	   our	   clinical	   observations,	   other	   groups	   have	   found	   that	  patients	   with	   diabetes	   mellitus	   have	   altered	   cell	   migratory	   patterns	   under	   both	  homeostatic	   and	   stressful	   conditions	   as	  well	   as	  other	   tissues	   such	  as:	   1)	  diabetics	  have	  a	  lower	  proportion	  of	  circulating	  haematopoietic	  progenitors162	  and	  a	  reduced	  homing	  capacity	  of	  medullary	  mononuclear	  cells	  in	  the	  ischemic	  myocardium	  163;	  2)	  gestational	   diabetes	   is	   associated	   with	   a	   statistically	   significant	   risk	   of	   fetal	  malformation164;	  3)	  wound	  healing	   is	   impaired	   in	  diabetic	  subjects165;	  4)	  diabetics	  are	  more	  infection-­‐prone166.	  	  
The	  healing	  of	  wounds,	  repair	  of	  organ	  damage,	  embryogenesis,	  neovascularisation	  and	   immune	   response	   presuppose	   a	   preserved	   directional	   migration	   capacity	   of	  certain	  types	  of	  cell	  attracted	  by	  a	  gradient	  (chemotaxis).	  	  
As	   diabetes	   influences	   the	   processes	   based	   on	   the	   cells’	   chemotactic/migratory	  capacity,	   the	   assumption	  underlying	   the	  project	   is	   that	  mobilization	   and	   stem	  cell	  engraftment	   regulation	   mechanisms	   are	   also	   altered	   by	   diabetes	   during	   HSC	  transplantation.	  	   
Based	  on	  these	  collective	  observations,	  our	  central	  thesis	  is	  that	  many	  of	  the	  pathophysiological	   complications	   of	   diabetes	   are	   due	   to	   a	   common	   systemic	   stem	  
and	  progenitor	  cell	   trafficking	  problem	  and	  therefore	  diabetes	  can	  be	  re-­‐examined	  as	   a	   stem	   cell	   disease.	   By	   extension	   this	   hypothesis	   presupposes	   that	   correcting	  these	   cell	   migratory	   failings	   will	   uncover	   new	   opportunities	   for	   designing	   an	  alternative	  class	  of	  anti-­‐diabetic	  therapies.	  
	   Therefore,	  the	  collective	  aims	  of	  this	  project	  was	  to	  determine	  the	  underlying	  physiological	   and	   molecular	   aberrations	   that	   cause	   defective	   HSPC	   trafficking	   in	  diabetes	  and	  examine	  whether	  these	  defects	  could	  be	  corrected.	  The	  results	  of	  the	  proposed	  experiments	  would	  not	  only	  provide	  novel	  mechanistic	  insights	  into	  how	  HSPC	   biology	   but	   would	   also	   establish	   the	   paradigm	   that	   diabetes,	   and	   possibly	  other	   chronic	   degenerative	   diseases,	   can	   be	   viewed	   as	   hematopoietic	   stem	   cell	  diseases.	  
MATERIALS	  &	  METHODS	  
Analysis	  of	  Mobilization	  Patient	  Caseload	  
Sixty-­‐two	   patients	   treated	   with	   G-­‐CSF	   to	   induce	   hematopoietic	   stem	   cell	  (HSC)	   mobilization	   at	   the	   Parma	   Bone	   Marrow	   Transplant	   Centre	   between	   1st	  January	  2004	   and	  30th	  October	  2008	  we	   assessed	   for	   overall	  mobilization	   failure	  rate	   as	   defined	   as	   <20	   CD34+	   and	   <3000	   polymorphonuclear	   (PMNs)	   cells/ml;	  <5,000	   leukocytes/ml;	   <50,000	   platelets/ml	   blood	   at	   the	   beginning	   of	  leukapheresis.	  	  
Nineteen	  cases	  of	  diabetes	  mellitus	  were	  identified	  (mean	  57±7	  yrs	  of	  age;	  10	  males)	   following	   the	   guidelines	   of	   the	   American	   Diabetes	   Association167.	   The	  interval	   from	   the	   documentation	   of	   diabetes	   to	   transplantation	   ranged	   from	   6	  months	   to	   5.3	   years.	   High	   levels	   of	   blood	   glucose,	   HbA1c	   >	   7	   gm%	   (PID	   5	  HBA1C=6.8,	   PID17	   HBA1C=6.7,	   PID1,8,9,12	   HBA1C	  missing)	   and	   need	   for	   insulin	  treatment	  were	  documented.	  In	  two	  cases	  (11%),	  diabetes	  mellitus	  was	  associated	  with	  the	  use	  of	  corticosteroids,	  whereas	  in	  the	  remaining	  cases	  type	  I	  or	  II	  diabetes	  were	  present.	  Controls	  consisted	  of	  43	  non-­‐diabetic	  subjects	  (52±12	  yrs;	  24	  males).	  The	  principal	  needs	  for	  autologous	  peripheral	  blood	  stem	  cell	  transplantation	  were	  clinical	  remission	  of	  multiple	  myeloma	  (42%),	  lymphoma	  (32%)	  and	  acute	  myeloid	  leukemia	  (26%).	  	  
Parameters	  for	  inducing	  and	  enumerating	  HSC	  mobilization	  
CD34+	   cells	   were	   counted	   using	   a	   Becton-­‐Dickinson	   FACSCalibur	   after	  erythrocyte	  lysis	  (EDTA-­‐ammonium	  chloride	  solution)	  and	  direct	  incubation	  for	  30	  
minutes	   with	   phycoerythrin	   (PE)	   conjugated	   monoclonal	   anti-­‐CD34	   (HPCA2,	  Becton-­‐Dickinson,	  San	   Jose,	  Ca,	  USA).	  CD34+	  cell	   counts	  were	  performed	   following	  ISHAGE	   logical	   gate	   protocol.	   A	   negative	   control	   for	   non	   specific	   fluorescence	  (Simultest;	   Becton	   Dickinson,	   Erembodegem-­‐Aalsi,	   Belgium)	   was	   used	   with	  unstained	  cells;	  the	  minimal	  number	  of	  events	  acquired	  for	  each	  determination	  was	  70,000	  and	  the	  entire	  procedure	  was	  performed	  at	  4	  °C.	  In	  all	  cases	  only	  the	  CD34+	  cell	  count	  performed	  in	  the	  lymphomonocyte	  gate	  was	  considered	  for	  data	  analysis.	  
Chemotherapy	  included	  high-­‐dose	  of	  cyclophosphamide	  (7	  g/m2),	  ifosfamide,	  carboplatin,	   etoposide	   (ICE)	  168	  or	   high-­‐dose	   Ara-­‐C	   and	   dexamethasone	   (DHAP)169	  regimens,	   which	   were	   equally	   employed	   in	   the	   two	   groups	   (See	   supplementary	  table	   1).	   Starting	   24	   hrs	   after	   the	   discontinuation	   of	   chemotherapy,	   G-­‐CSF	   (10	  ug/kg/day,	   Roche,	   Basel,	   Switzerland)	   was	   subcutaneously	   given	   until	  leukapheresis.	   From	   day	   9	   after	   priming,	   circulating	   CD34+	   cells	   were	  monitored	  daily.	   The	   following	   parameters	   were	   used	   as	   criteria	   for	   the	   beginning	   of	  leukapheresis:	   CD34+	   cells	   ≥	   20/uL	   and/or	   PMNs	   ≥	   3000/uL,	   leukocyte	   count	   ≥	  5,000/uL,	  platelet	  count	  ≥	  50,000/uL.	  
Mouse	  models	  of	  Diabetes	  –	  Type	  I	  Diabetes	  
For	  our	  mouse	  model	  of	  type	  I	  diabetes,	  C57BL/6	  male	  mice	  were	  treated	  for	  five	  consecutive	  days	  with	  a	  single	  intraperitoneal	  injection	  of	  streptozotocin	  (STZ)	  diluted	  in	  citrate	  pH	  4.5	  	  (50	  mg/kg/die	  in	  one	  daily	  dose).	  Mice	  injected	  with	  citrate	  buffer	  were	  used	  as	  controls.	   STZ	   is	  a	  glucose	  analog	   that	   is	   taken	  up	  by	  and	  kills	  pancreatic	  beta	  cells,	  which	  subsequently	  causes	  a	  decline	  of	  systemic	  insulin	  levels	  
with	  a	  concomitant	  increase	  in	  blood	  glucose	  levels.	  Therefore,	  successful	  induction	  of	   diabetes	   following	   STZ-­‐treatment	   was	   determined	   by	   measuring	   blood	   insulin	  and	  glucose	  levels	  by	  ELISA	  (R&D	  System)	  and	  Glucometer	  (One	  Touch	  Ultra®).	  
Mouse	  models	  of	  Diabetes	  –	  Type	  II	  Diabetes	  
The	   mutant	   leptin	   receptor	   (db)	   mice	   were	   purchased	   from	   the	   Jackson	  laboratories	  	  (Bar	  Harbor,	  ME)	  and	  heterozygous	  (db/+)	  mice	  were	  bred	  together	  to	  generate	   homozygous	   (db/db)	   mice.	   Mice	   were	   genotyped	   using	   the	   protocol	  recommended	  by	  Jackson	  Laboratories.	  Homozygous	  (db/db)	  mice	  become	  obese	  by	  4-­‐6	  weeks	  and	  develop	  diabetes	  shortly	  thereafter.	  The	  diabetic	  status	  of	  mice	  was	  determined	   by	  measuring	   insulin	   and	   glucose	   levels	   by	   ELISA	   (R&D	   System)	   and	  Glucometer	   (One	   Touch	   Ultra®),	   respectively.	  Wild	   type	   littermates	  were	   used	   as	  controls	  against	  db/db	  mice.	  
Bone	  marrow	  cell	  isolation	  




All	  bone	  marrow	  transplantations	  were	  performed	  by	  tail	  vein	  injection.	  The	  C57BL/6	   background	   expresses	   the	   CD45.2	   congenic	   polymorphism	   on	   all	  hematopoietic	  tissues.	  Both	  of	  our	  Type	  I	  (i.e.	  STZ-­‐induced)	  and	  Type	  II	  (i.e.	  db/db	  mice)	  models	  used	  mice	  of	  the	  C57BL/6	  background	  and	  are	  therefore	  express	  the	  CD45.2	   congenic	  marker.	   C57BL/6.SJL	  mice	   (available	   from	   Jackson	   Laboratories)	  express	   the	   CD45.1	   congenic	   marker.	   All	   transplantation	   assays	   involved	  transplanting	   bone	   marrow	   (BM)	   cells	   from	   C57BL/6	   mice	   (CD45.2+)	   into	   SJL	  recipient	  mice	  (CD45.1+),	  which	  allows	  us	  to	  distinguish	  between	  BM	  cells	  generate	  by	  the	  donor	  versus	  the	  recipient.	  Moreover,	  for	  competitive	  transplantation	  assays	  we	  used	  donor	  BM	  that	  was	  CD45.2+	  and	  both	  the	  competitor	  and	  the	  recipients	  BM	  cells	   were	   derived	   from	   SJL	   mice	   (CD45.1).	   Prior	   to	   transplantation,	   all	   recipient	  mice	   were	   conditioned	   with	   9.5cGy	   of	   irradiation	   to	   lethally	   ablate	   the	   recipient	  bone	  marrow	  cells	  –	   this	   is	  particularly	   important	  because	   this	  dose	  of	   irradiation	  kills	   resident	   recipient	   HSCs	   and	   evacuates	   the	   niche,	   which	   provides	   space	   for	  engraftment	  of	  donor	  HSCs.	  Mice	  are	  then	  administered	  acidic	  water	  supplemented	  with	  antibiotics	   for	  21	  days.	  To	  assess	  the	  engraftment	  contribution	  of	  both	  donor	  and	  competitor	  BM	  cells,	   either	  peripheral	  blood	   (extracted	   from	   the	   retro-­‐orbital	  vein)	  or	  bone	  marrow	  (taken	  from	  the	   long	  bones)	  were	   first	   lysed	  to	  remove	  red	  blood	   cells	   and	   the	   remaining	  mono-­‐nuclear	   cells	   (MNCs)	  were	   then	   stained	  with	  fluorescently	   labeled	   antibodies	   that	   specifically	   recognize	   CD45.1	   and	   CD45.2.	  Labeled	  MNCs	  cells	  were	  then	  analysed	  by	  flow	  cytometry	  to	  determine	  the	  percent	  contribution	  of	  donor	  and/or	  competitor	  populations.	  
HSC	  mobilization	  in	  mice	  
To	  induce	  HSPC	  mobilization,	  mice	  were	  administered	  8	  injections	  of	  human	  recombinant	   125	   mg/Kg/day	   G-­‐CSF	   (Filgastrim,	   Amgen)	   every	   12	   hours	   intra-­‐peritoneal	   (i.p.).	   Three	   hours	   following	   the	   final	   G-­‐CSF	   injection,	   peripheral	   blood	  (PB)	  was	  extracted	  from	  the	  retro-­‐orbital	  vein	  of	  mice.	  Mobilized	  progenitors	  were	  quantified	  as	  described	  below.	  
Enumeration	  of	  mobilized	  HSPCs	  
We	   quantified	   the	   number	   of	   hematopoietic	   stem	   and	   progenitor	   cells	  (HSPCs)	  using	  both	  in	  vitro	  and	  in	  vivo	  methods.	  For	  in	  vitro	  enumeration	  of	  HSPCs:	  50ul	  of	  PB	  was	  plated	   in	  methylcellulose	   supplemented	  with	   recombinant	  murine	  GM-­‐CSF,	  IL-­‐3,	  IL-­‐6	  and	  EPO	  (M3434,	  Stem	  Cell	  Technologies,	  British	  Columbia,	  CA)	  culture	  for	  7	  days	  and	  then	  assessed	  for	  colony	  formation–	  each	  colony	  representing	  an	   HSPC	   (CFU-­‐C	   assay).	   For	   in	   vivo	   analysis:	   100-­‐150uL	   of	   mobilized	   blood	   was	  injected	   into	   lethally	   irradiated	   (9.5	  Gy)	   the	   SJL	   congenic	   strain	   of	   C57BL/6	   –	   SJL	  mice	   (as	   described	   above).	   HSPC	   engraftment	   was	   monitored	   weekly	   by	  determining	  the	  percent	  donor	  CD45+	  cells	  in	  the	  recipient	  PB	  by	  FACS	  analysis	  (as	  described	  above).	  	  
Immunophenotypic	  analysis	  of	  BM	  
Mice	   were	   sacrificed	   via	   CO2	   asphyxia	   and	   then	   tibias,	   femurs,	   and	   spinal	  bones	   were	   removed	   and	   excess	   soft	   tissue	   was	   eliminated.	   Using	   a	   pestle	   and	  mortar,	   the	   bones	   were	   crushed	   and	   washed	   in	   PBS	   with	   0.5%	   FBS	   and	   passed	  
through	   a	   40μm	   filter	   into	   a	   collection	   tube.	   Cells	   were	   spun	   at	   1500rpm	   for	   5	  minutes;	   the	   supernatant	  was	   removed,	   and	  cells	  were	   then	   further	  processed	   for	  either	   staining,	   sorting	   or	   for	   bone	   marrow	   transplantation.	   Hematopoietic	   stem	  progenitors	  were	  identified	  based	  on	  their	  expression	  of	  lineage	  markers	  as	  well	  as	  c-­‐Kit,	  Sca-­‐1	  and	  CD48,	  CD150	  or	  CD34,	  CD135	  (Flk-­‐2)	  expression.	  Lineage	  staining	  was	  performed	  using	  a	  cocktail	  of	  biotinylated	  anti-­‐mouse	  antibodies	  against	  Mac-­‐1	  (CD11b),	   Gr-­‐1	   (Ly-­‐6G	   and	   Ly-­‐6C),	   Ter119	   (Ly-­‐76),	   CD3 ,	   CD4,	   CD8a	   (Ly-­‐2),	   and	  B220	   (CD45R)	   (BD	   Biosciences).	   For	   detection	   we	   used	   lineage-­‐streptavidin	  conjugated	  with	  PacOrange	  (Invitrogen)	  fluorescent	  mareker	  and	  then	  subsequently	  stained	  with	   c-­‐Kit-­‐APC	   (CD117),	   Sca1-­‐APC-­‐Cy7	   and	   either	   CD48-­‐FITC	  +	  CD150-­‐PE	  (CD135)	  –	   for	  SLAM	  HSC	  analysis	  or	  CD34-­‐FITC	  +	  Flk2-­‐PE	  for	  alternative	  LT-­‐HSCs	  immunophenotyping	   (BD	   Biosciences).	   	   For	   congenic	   strain	   discrimination,	   anti-­‐CD45.1-­‐APC	   and	   anti-­‐CD45.2	   FITC	   antibodies	   (BD	   Biosciences)	   were	   used.	  Compensation	   and	   data	   analysis	  were	   performed	  with	   Flowjo	   8.5.3.	   For	   cell	   cycle	  staining	  cells	  were	  fixed	  overnight	  in	  70%	  ethanol,	  washed	  twice	  in	  PBS	  and	  stained	  with	  a	  solution	  containing	  propidium	  iodide,	  RNAse	  A	  in	  Triton	  X	  0.1%.	  	  
Flow	  cytometric	  analysis	  of	  adhesion	  molecules	  
To	   examine	   the	   cell	   surface	   expression	   of	   the	   adhesion	   molecules	   CXCR4,	  CD49D,	   CD49E,	   CD62L	   on	   HSPCs,	   bone	   marrow	   mono-­‐nuclear	   cells	   (BM-­‐MNCs)	  were	   recovered	   form	  both	  STZ-­‐treated	  and	  control	  mice	  and	  stained	  with	   lineage,	  cKIT	   and	   Sca-­‐1	   antibodies	   as	   described	   above.	   Stained	   BM-­‐MNCs	   from	   each	  experimental	   condition	  were	  divided	   into	  4	   tubes	  and	  separately	  stained	  with	  PE-­‐
conjugated	   forms	   of	   CXCR4,	   CD49D,	   CD49E	   or	   CD62L	   antibodies	   (eBioscience).	  Stained	   cells	   were	   then	   subjected	   to	   flow	   cytometry	   and	   analyzed	   as	   described	  above.	  
Transwell	  migration	  assays	  (Modified	  Boyden	  chamber	  assay)	  
For	  migration	  assays,	  2	  ×	  103	  FACS-­‐sorted	  LSK	  cells	  were	  suspended	  in	  500	  μl	  of	  RPMI	  and	  seeded	  in	  triplicate	  in	  the	  upper	  chamber	  of	  24-­‐well,	  5-­‐μm	  Transwell	  plates	  (Corning).	  Cells	  were	  incubated	  for	  1	  hour	  at	  37°C	  in	  the	  presence	  or	  absence	  of	  SDF-­‐1α	  (stromal	  cell–derived	   factor	  1α	  also	  known	  as	  CXCL12),	  after	  which	   the	  supernatant	   was	   removed	   and	   the	   wells	   were	   washed	   once	   with	   PBS	   to	   remove	  nonadherent	   cells.	   Adherent	   cells	   were	   harvested	   by	   treatment	   with	   cell	  dissociation	  buffer,	  enzyme-­‐free	  (Invitrogen),	  and	  plated	  in	  methylcellulose	  (CFC-­‐U	  assay	  described	  above).	  
Adhesion	  Assay	  	  
For	  adhesion	  assays,	  2	  ×	  103	  FACS-­‐sorted	  LSK	  cells	  were	  plated	  in	  triplicate	  on	  24-­‐well	  culture	  dishes	  precoated	  with	  fibronectin	  for	  4	  hours.	  Next,	  the	  adherent	  fraction	   was	   dissociated	   by	   treatment	   with	   cell	   dissociation	   buffer,	   enzyme-­‐free	  (Invitrogen),	   collected,	   and	   plated	   in	   MethoCult	   media	   (M3434,	   Stemcell	  Technologies).	  Progenitor	  adhesion	  was	  determined	  as	   the	  percentage	  of	  CFU-­‐C	   in	  the	  adherent	  fractions	  relative	  to	  the	  frequency	  of	  CFU-­‐C	  in	  the	  input	  sample.	  
Assessment	  of	  cellular	  and	  secreted	  Cxcl12	  
CXCL12	   labeling	   was	   performed	   using	   Monoclonal	   Anti-­‐human/mouse	  CXCL12	   Antibody	   Clone	   79018	   after	   fixation	   and	   permeabilization	   (BD	  cytofix/cytoperm	   kit)	   followed	   by	   secondary	   goat	   anti-­‐mouse	   IgG-­‐PE	   (both	   from	  R&D	  systems).	  Both	  peripheral	  blood	  and	  bone	  marrow	  SDF1	  levels	  were	  quantified	  using	  ELISA	  (R&D	  System).	  
RNA	  isolation	  and	  quantitative	  real	  time	  RT-­PCR	  
Nestin	  and	  Col2.3	  cells	  were	  FACS	  sorted	   for	  GFP	  protein	  directly	   into	   lysis	  buffer	   and	   RNA	   isolation	   was	   performed	   using	   the	   Dynabeads	   mRNA	   DIRECT	   TM	  Micro	   kit	   (Invitrogen).	   Primer	   sequences	   and	   RT-­‐PCR	   procedure	   used	   have	   been	  previously	  described120.	   	  
Adhesion	  and	  migration	  assays	  
For	  adhesion	  assays:	  2	  x	  103	  FACS	  sorted	  LSK	  cells	  were	  plated	  in	  triplicate	  on	   24-­‐well	   culture-­‐dishes	   pre-­‐coated	  with	   fibronectin.	   The	   adherent	   fraction	  was	  dissociated	   by	   treatment	   with	   Cell	   Dissociation	   Buffer,	   enzyme-­‐free	   (Invitrogen),	  collected	   and	   plated	   in	   MethoCult	   media	   (M3434,	   Stem	   cell	   technologies).	  Progenitor	   adhesion	  was	   determined	   as	   the	   percentage	   of	   CFU-­‐C	   in	   the	   adherent	  fractions,	  relative	  to	  the	  frequency	  of	  CFU-­‐C	  in	  the	  input	  sample.	  
For	  migration	  assays:	  2	  x	  103	  FACS	  sorted	  LSK	  cells	  were	  suspended	   in	  500	  uL	  of	  RPMI	   and	   seeded	   in	   triplicate	   in	   the	   upper	   chamber	   of	   24-­‐well,	   5-­‐um	   Transwell	  plates	  (Corning,	  Lowell,	  MA).	  Cells	  were	  incubated	  for	  1	  h	  at	  37ºC	  in	  the	  absence	  or	  presence	  of	  SDF1-­‐α,	  after	  which	  the	  supernatant	  was	  removed	  and	  the	  wells	  were	  
washed	  once	  with	  PBS	  to	  remove	  non-­‐adherent	  cells.	  Adherent	  cells	  were	  harvested	  by	   treatment	  with	  Cell	  Dissociation	  Buffer,	  enzyme-­‐free	  (Invitrogen)	  and	  plated	   in	  methylcelullose.	  Progenitor	  adhesion	  was	  determined	  as	  above	  mentioned.	  
Imaging	  of	  the	  HSC	  niche	  
Mice	   were	   anesthetized	   and	   prepared	   for	   in	   vivo	   imaging	   as	   previously	  described43.	   FACS-­‐sorted	   HSCs	   were	   stained	   in	   PBS	   for	   15	  min	   at	   37°C	   with	   DiD	  (Invitrogen)	   or	   DiI	   (Invitrogen)	   using	   a	   1:200	   dilution	   and	   injected	   into	   lethally	  irradiated	   recipients.	   An	   about	   4	   ×	   6–mm	   area	   of	   the	   calvarium	   comprising	   the	  central	   sinus	   and	   the	   surrounding	   bone	  marrow	   cavities	  within	   the	   left	   and	   right	  frontal	   bones	  was	   scanned.	  When	  using	   Col2.3GFP	   and	  Nestin-­‐GFP	   reporter	  mice,	  three-­‐dimensional	  models	  of	  the	  osteoblastic	  or	  nestin	  cells	  and	  the	  bone	  (second-­‐harmonic	   generation)	   were	   developed	   through	   Z-­‐stack	   reconstruction.	   Using	   the	  Pythagoric	  theorem,	  we	  determined	  the	  location	  of	  stained	  HSCs	  injected	  in	  relation	  to	   the	   bone	   and	   the	   GFP+	   cells.	   The	   images	   were	   analyzed	   with	   ImageJ	   software	  (National	  Institutes	  of	  Health;	  http://rsbweb.nih.gov/ij/).	  
Immunostaining	  of	  mice	  calvaria	  
Calvaria	  from	  diabetic	  and	  control	  mice	  were	  fixed	  in	  4%	  paraformaldehyde	  for	   1	   hour	   and	   subsequently	  washed	   twice	   in	   PBS.	   Blocking	   of	   unspecific	   binding	  and	  permeabilization	  were	  achieved	  with	  20%	  goat	  serum	  and	  0.5%	  Triton	  X-­‐100	  in	  PBS	  overnight.	  Endogenous	  biotin	  was	  blocked	  with	  Vector	  Kit	  (catalog	  number	  Sp-­‐2001)	   following	   the	   manufacturer’s	   instructions.	   Primary	   antibody	   (Chemicon	  rabbit	   anti–tyrosine	   hydroxylase;	   BD	  Pharmingen	  APC-­‐conjugated	   anti-­‐CD31)	  was	  
applied	  at	  1:100	  in	  20%	  goat	  serum	  and	  0.1%	  Triton	  X-­‐100	  in	  PBS	  and	  incubated	  for	  2	   to	   3	   days.	   Samples	  were	  washed	  with	   0.1%	  Triton	   X-­‐100	   in	   PBS	   and	   incubated	  overnight	  with	   a	   secondary	  biotinylated	   goat	   anti-­‐rabbit	   antibody	   (1:200)	   in	  20%	  goat	  serum	  and	  0.1%	  Triton	  X-­‐100	  in	  PBS.	  After	  washing	  with	  0.1%	  Triton	  X-­‐100	  in	  PBS,	  samples	  were	   incubated	  for	  2	  hours	  with	  ABC	  kit	  (Vector	  PK-­‐6100)	  prepared	  30	   min	   before	   use.	   After	   washes	   with	   PBS,	   samples	   were	   incubated	   with	   Cy3-­‐tyramide	   (Perkin	  Elmer)	   (1:200)	   in	  diluent	   reagent	   for	  30	  min,	  washed	  with	  PBS,	  and	  visualized	  by	  fluorescence	  microscopy.	  Projections	  of	  Z-­‐stacks	  (100	  to	  200	  μm)	  of	   calvaria	   bone	   marrow	   were	   analyzed	   with	   the	   SlideBook	   software	   (Intelligent	  Imaging	  Innovations).	  
Drugs	  administration	  	  
A	  single	  injection	  of	  isoproterenol	  (Sigma;	  5	  mg/kg:	  i.p.)	  was	  administered	  to	  diabetic	  and	  control	  mice.	  SR	  59230A	  (Sigma;	  5	  mg/kg:	  i.p)	  was	  administered	  daily	  for	  10	  days	  to	  diabetic	  mice.	  	  
Mice	   treated	  with	   saline	  were	  used	   as	   a	   control.	  Animals	  were	   sacrificed	  2	  hours	  after	   injection	  by	  CO2	  asphyxia	  and	  the	   femora	  were	   flushed	  with	  200	  uL	  of	  PBS.	  Trizol	  (Invitrogen)	  was	  used	  for	  total	  RNA	  extraction.	  	  
Osteoblastic	  cell	  deletion	  
Mice	   in	   which	   expression	   of	   Cre-­‐recombinase	   was	   driven	   by	   Osteocalcin	  promoter	  were	   crossed	  with	  mice	   harboring	   an	   inducible	   Difteria	   Toxin	   Receptor	  transgene	   (iDTR)170,171.	   In	   the	   double	   transgenic,	   Cre-­‐mediated	   removal	   of	   a	  
transcriptional	   STOP	   cassette	   allows	   the	   expression	   of	   DT	   receptor.	   Upon	   DT	  administration	   efficient	   ablation	   of	   the	   target	   population	  was	   achieved.	  Mice	  with	  only	  one	  transgene	  were	  used	  as	  controls.	  Both	  double	  and	  single	   transgenic	  mice	  were	  treated	  with	  either	  STZ	  for	  diabetes	  induction	  or	  with	  saline.	  After	  5	  weeks,	  DT	  was	   administered	   at	   the	  dose	   of	   100	  ng	  per	  mouse	   twice	   a	   day	   for	   14	  days.	  Nine	  days	  after	  starting	  the	  toxin	  administration	  G-­‐CSF	  was	  administered	  (8	  injections	  of	  125	  ugr/kg	   every	   12	  hrs).	   At	   days	   14,	   blood	  was	   collected	   and	  used	   for	   flow	   and	  transplantation	  assays.	  
ELISA	  
CXCL12	   protein	   levels	  were	   assessed	   in	   bone	  marrow	   supernatant	   and	   PB	  plasma.	  Briefly	   femurs	   from	  diabetic	   and	  control	  mice	  were	   flushed	  4	   times	  using	  100	  uL	  of	  PBS	  (total	  volume)	  in	  Eppendorf	  tubes.	  PB	  was	  collected	  via	  retroorbital	  bleeding	  in	  Eppendorf	  tubes	  without	  adding	  anti-­‐coagulant.	  The	  samples	  were	  then	  incubated	  at	  37ºC	  for	  1	  hr	  and	  spun	  at	  4.6	  rpm	  for	  5	  min.	  Plasma	  was	  then	  collected	  and	   used	   for	   CXCL12	   evaluation	   with	   ELISA	   kit	   (Ray	   Biosystem)	   following	  manufacturer	  instructions.	  	  
Insulin	   levels	   were	   assessed	   in	   PB	   plasma	   with	   ELISA	   kit	   (Crystal	   Chem.	   Inc)	  following	  manufacturer	  instructions.	  
Western	  blot	  
Nestin-­‐GFP	  cells	  were	  sorted	  using	  FACS-­‐aria.	  Western	  blot	  was	  performed	  using	  antibody	  antPhopho-­‐PKA	  (Invitrogen)	  following	  manufacturer	  instruction.	  	  	  
Statistical	  analysis	  
Mice:	  Unless	  otherwise	  specified,	  unpaired,	  2-­‐tailed	  Student’s	  t	  test	  was	  used	  and	  data	  have	  been	  plotted	  as	  average	  ±	  s.e.m.	  Statistical	  significance	  is	  indicated	  by	  *	  (p<0.05)	  or	  **	  (p<0.01)	  or	  ***	  (p<0.001).	  
Human:	   Fisher’s	   exact	   test	  was	   used	   to	   compare	   the	   frequency	   of	   diabetes	  between	   poor	   and	   good	   mobilizers.	   The	   Wilcoxon	   two-­‐sample	   test	   was	   used	   to	  compare	   the	   distribution	   of	   CD34+	   cell/kg	   and	   glucose	   levels	   between	   patient	  groups.	  Neutrophil	  recovery	  and	  platelet	  engraftment	  were	  measured	  from	  the	  day	  of	  transplantation	  with	  peripheral	  blood	  stem	  cells	  or	  bone	  marrow	  harvested	  cells.	  The	   cumulative	   incidence	   of	   engraftment	   was	   estimated	   using	   the	   Kaplan-­‐Meier	  method,	   and	   the	   difference	   between	   diabetic	   and	   non-­‐	   diabetic	   patients	   was	  assessed	  by	  the	  logrank	  test.	  All	  p-­‐values	  were	  based	  on	  a	  two-­‐sided	  hypothesis	  and	  were	  computed	  using	  SAS	  9.2.	  (SAS	  Inst.).	  
	  RESULTS	  
After	   reviewing	   a	   caseload	   of	   patients	   mobilized	   with	   G-­‐CSF	   in	   the	   Parma	  Bone	  Marrow	  Transplant	  Centre	  between	  1st	  January	  2004	  and	  30th	  October	  2008,	  we	  observed	  a	  mobilization	  failure	  rate	  of	  22.6%	  (n=62)	  (Figure	  3).	  Seven	  of	  the	  14	  ‘poor-­‐mobilizers’	   were	   diabetic	   whereas	   only	   25%	   of	   ‘good	   mobilizers’	   were	  diabetic.	   To	   determine	   the	   cellular	   and	  molecular	   underpinnings	   of	   the	   increased	  frequency	   of	   poor	   G-­‐CSF-­‐mediated	  mobilization	   observed	   in	   diabetic	   patients	   our	  first	  goal	  was	  to	  recapitulate	  the	  phenotype	  in	  a	  small	  animal	  model	  of	  diabetes.	  	  
We	   elected	   to	   utilize	   two	   murine	   models	   of	   diabetes	   that	   separately	  recapitulate	   both	   types	   of	   human	   diabetes.	   	   To	   mimic	   type	   I	   diabetes,	   where	   in	  humans	  the	  primary	  defect	  is	  the	  lack	  of	  production	  of	  insulin	  by	  the	  pancreatic	  beta	  cells,	  we	   treated	  mice	  with	   streptozotocin,	  which	   is	   an	  analogue	  of	   glucose	   that	   is	  taken	  up	  by	  pancreatic	  cells	  and	  subsequently	  kill	  them.	  To	  model	  type	  II	  diabetes,	  where	  the	  primary	  defect	  in	  humans	  is	  a	  cell	  resistance	  to	  the	  insulin,	  we	  used	  mice	  that	   lack	   the	   leptin	   receptor	   (db/db	   mice),	   which	   promotes	   insulin	   resistance	   in	  adipose	  and	  muscle	  tissues.	  	  
	   As	  mentioned	  in	  the	  rationale	  section,	  we	  observed	  that	  poor	  mobilization	  in	  response	   to	   G-­‐CSF	   correlated	   with	   an	   increased	   frequency	   of	   diabetes	   as	   well	   as	  increased	   serum	   glucose	   levels	   (Figure	   4a-­‐c).	   Therefore,	   we	   first	   measured	   the	  glucose	  levels	  (described	  in	  the	  materials	  &	  methods)	  of	  all	  STZ-­‐treated	  and	  db/db	  mice	   and	   reassigned	   mice	   into	   4	   experimental	   groups	   based	   on	   serum	   glucose	  
levels:	   Group	   A	   (<150mg/dl),	   Group	   B	   (150-­‐200mg/dl),	   Group	   C	   (200-­‐300mg/dl)	  and	  Group	  D	  (>300mg/dl).	  Mice	  from	  each	  group	  were	  then	  administered	  8	  doses	  of	  62.5mg/kg	  G-­‐CSF,	  separated	  by	  12	  hours	  each	  (see	  materials	  &	  methods).	  Following	  the	  last	  G-­‐CSF	  treatment,	  peripheral	  blood	  (PB)	  was	  extracted	  from	  mice	  and	  either	  cultured	   in	   cytokine-­‐enriched	   methylcellulose	   to	   enumerate	   mobilized	   functional	  HSPCs	  or	  assessed	  by	  flow	  cytometry	  to	  quantify	   immunophenotypic	  HSPCs.	  From	  these	   assays	   we	   observed	   an	   inverse	   correlation	   of	   serum	   glucose	   to	   G-­‐CSF	  mediated	   HSPC	   mobilization	   as	   measured	   by	   either	   flow	   cytometry	   or	   colony	  forming	  units	  –	  statistically	  validated	  by	  both	  two-­‐tailed,	  non-­‐parametric	  student	  T	  test	   as	  well	   as	   a	   Jonckheere-­‐Terpstra	   test,	  which	   an	   additional	   test	   reputed	   to	   be	  more	  robust	  for	  evaluating	  cohorts	  of	  different	  size.	  (Figures	  5a-­‐b).	  
Since	  type	  I	  (STZ-­‐induced)	  and	  type	  2	  (db/db)	  diabetes,	  are	  characterized	  by	  insulin	  deficiency	  and	  hyperinsulinemia,	  respectively	  we	  also	  examined	  whether	  there	  was	  a	   correlation	   between	   insulin	   levels	   and	   the	   efficacy	   of	   G-­‐CSF-­‐induced	   HSPC	  mobilization.	   Insulin	   levels	  varied	  according	   to	   the	  model	   (low	   in	  STZ	  and	  high	   in	  db/db),	   but	  we	   did	   not	   observe	   any	   significant	   correlation	   between	   insulin	   levels	  and	   HSPC	  mobilization.	   However,	   we	   did	   find	   that	   plasma	   insulin	   concentrations	  were	   low/absent	   (0.1±	   0.2	   ng/ml)	   or	   high	   (30±8	  ng/ml)	   in	   the	   poorest	  mobilizer	  groups	  of	   STZ-­‐induced	  and	  db/db	  mice,	   respectively.	  Mice	   from	  either	  model	   that	  had	   lower	   glycemic	   levels	   showed	   plasma	   insulin	   levels	   within	   the	   normal	   range	  (1.1±0.3	   ng/ml).	   These	   results	   suggest	   that	   the	   rate	   of	   reduction	   in	   HSPC	  mobilization	  caused	  by	  diabetes	  is	  proportional	  to	  glucose	  levels	  but	  independent	  of	  insulin	  concentration.	  	  
	   Although	  the	  causes	  of	  the	  two	  different	  types	  of	  diabetes	  vary,	  both	  diseases	  lead	   to	   the	   development	   of	   similar	   vascular	   and	   neural	   complications,	   which	   are	  related	  to	  the	  chronic	  hyperglycemia	  observed	  in	  both	  diseases.	  Since	  we	  observed	  a	  similar	  mobilization	  defects	  in	  both	  mice	  models,	  we	  elected	  to	  use	  the	  STZ	  mouse	  model	  to	  elucidate	  the	  mechanism	  at	  the	  bases	  of	  the	  mobilization	  defect.	  
Concamitant	  with	  the	  reduction	  in	  mobilized	  	  HSPCs	  we	  observed	  using	  the	  in	  vitro	  CFU-­‐C	  model,	  we	  also	  observed	  in	  vivo	  when	  we	  transplanted	  mobilized	  blood	  into	  lethally	  irradiated	  syngeneic	  recipient	  mice	  (Figure	  6a-­‐c)	  (see	  Materials	  &	  Methods	  for	  technical	  details).	  
	   We	  hypothesized	  that	  the	  observed	  reduction	  in	  HSPC	  mobilization	  could	  be	  due	   to	   either	   a	   global	   reduction	   HSPC	   content	   in	   the	   BM	   of	   diabetic	   mice	   or	   a	  primary	  defect	   in	  migratory	  properties	  of	  HSPCs	  as	  well	  as	  a	  combination	  of	  both.	  Consistent	  with	  the	  former	  notion,	  the	  HSPC	  content	  is	  reduced	  in	  the	  BM	  of	  diabetic	  rats	  7,172.	  Therefore,	  we	  quantified	  the	  number	  of	  immunophenotypic	  LT-­‐HSCs	  in	  the	  BM	  of	  STZ-­‐treated	  diabetic	  mice	  using	  both	  SLAM	  markers	   (Lineagelow,	   cKit+,	   Sca-­‐1+,	   CD150+,	   CD48-­‐)	   as	   well	   as	   CD34	   and	   Flk2	   (Lineagelow,	   cKit+,	   Sca-­‐1+,	   CD34-­‐,	  Flk2-­‐)	   (methods	   for	   extracting	   BM,	   antibody	   staining	   and	   flow	   cytometry	   are	  described	   in	  materials	  &	  methods).	  Much	   to	  our	   surprise	   and	   in	   contrast	   to	   those	  observations	   made	   in	   diabetic	   rates	   we	   found	   that	   diabetic	   mice	   displayed	   an	  increased	  number	  of	  LSK	  progenitors	  per	  femur	  while	  the	  total	  number	  of	  LT-­‐HSCs	  was	   not	   significantly	   different	   in	   diabetic	   and	  non-­‐diabetic	  marrow	   (Figure	   7a-­‐d).	  However,	  it	  is	  possible	  that	  LT-­‐HSC	  function	  could	  be	  affected	  without	  a	  significant	  
change	   in	   immunophenotype.	   Therefore,	  we	   took	  mononuclear	   cells	   (MNCs)	   from	  both	   diabetic	   and	   non-­‐diabetic	   mice	   and	   separately	   examined	   their	   ability	   to	  reconstitute	  hematopoiesis	  in	  lethally	  irradiated	  recipient	  mice	  in	  competition	  with	  normal	   unconditioned	   BM	   (Figure	   7e).	   As	   predicted,	   recipient	   mice	   transplanted	  with	   a	   1:1	  mixture	   of	   non-­‐diabetic	   BM	  MNCs	   (CD45.2)	   and	   competitor	   BM	  MNCs	  (CD45.2)	   displayed	   a	   50%	   hematopoietic	   contribution	   from	   non-­‐diabetic	   BM	  (%CD45.2	  –	  Figure	  6f).	  Consistent	  with	  the	  increased	  number	  of	  immunophenotypic	  HSPCs	  we	  observed	  in	  the	  BM	  of	  diabetic	  mice,	  we	  also	  observed	  that	  MNCs	  derived	  from	   diabetic	   mice	   have	   an	   enhanced	   ability	   to	   competitively	   reconstitute	  hematopoiesis	   in	   lethally	   irradiated	   recipient	   mice	   (%CD45.2	   –	   Figure	   7f).	   These	  results	  suggest	  that	  the	  primary	  cause	  of	  reduced	  stem	  cell	  mobilization	  in	  response	  to	   G-­‐CSF	   treatment	   in	   diabetes	   could	   be	   a	   consequence	   of	   altered	   migratory	  signals/ability.	  Interestingly,	  when	  analyzing	  the	  donor	  (CD45.1)	  chimerism	  in	  these	  transplants	  we	  found	  that	  80%	  of	  the	  donor	  derived	  peripheral	  blood	  cells	  were	  of	  myeloid	   lineage	   (CD45.1,	   Gr1+,	   Mac1+).	   In	   contrast,	   myeloid	   cells	   constitute	   only	  40%	  of	  the	  total	  PB	  cells	  when	  donor	  cells	  were	  derived	  form	  non-­‐diabetic	  animals.	  This	   result	   suggests	   that	   diabetic	   stem	   progenitor	   cells	   are	   skewed	   toward	   the	  myeloid	  lineage	  (data	  not	  shown).	  	  
Given	  that	  our	  results	  that	  stem	  cell	  trafficking	  might	  be	  altered	  in	  diabetes	  and	  that	  HSPC	  migration	  is	  regulated	  by	  signals	  from	  the	  niche	  we	  hypothesized	  that	  diabetes	   could	  be	  disturbing	   the	  microenvironment	   signals	   that	  mediate	   stem	  cell	  motion.	  Before	  proceeding	   to	   test	   this	   hypothesis	  we	   first	  wanted	   to	   confirm	   that	  the	  diabetic	  process	  did	  not	  primarily	  affect	  HSCs.	  
HSPC	  mobility	  is	  largely	  influenced	  by	  chemokine	  gradients	  and	  the	  presence	  of	   adhesion	   molecules	   that	   anchor	   HSPCs	   –	   two	   factors	   that	   are	   not	   necessarily	  mutually	   exclusive.	   CXCR4,	   CD49D,	   CD49E	   and	   CD62L	   are	   cell	   surface	   proteins	  known	   to	   influence	   both	   HSPC	   adhesion	   and	   migration.	   Therefore,	   we	   first	  examined	  the	  expression	  of	  these	  cell	  surface	  markers	  on	  HSPCs	  from	  both	  diabetic	  and	   non-­‐diabetic	   mice.	   From	   these	   analyses,	   we	   found	   that	   HSPCs	   purified	   from	  diabetic	  mice	  displayed	  a	   significant	   increase	   in	  CD62L	   (also	  known	  as	  L-­‐selectin)	  expression	  compared	  to	  control	  HSPCs	  (Figure	  8a,c).	  However,	  We	  did	  not	  observe	  a	  significant	  difference	  in	  the	  expression	  of	  CXCR4,	  CD49D	  or	  CD49E	  between	  the	  two	  conditions	  (Figure	  8a,c)	  nor	  did	  we	  find	  any	  significant	  difference	  in	  the	  frequency	  HSPCs	  that	  express	  CXCR4,	  CD49D,	  CD49E	  or	  CD62L	  between	  the	  two	  experimental	  conditions	  (Figure	  8b).	  Next,	   we	   aimed	   to	   evaluate	   whether	   the	   cell	   mobility	   properties	   of	   HSPCs	  from	   both	   diabetic	   and	   non-­‐diabetes	  mice	   possessed	   differing	   abilities	   to	  migrate	  toward	  the	  HSPC	  chemo-­‐attractant	  SDF-­‐1a	  (also	  referred	  to	  as	  Cxcl12).	  To	  address	  this	   question,	   HSPCs	   FACS-­‐purified	   from	   each	   experimental	   condition	   were	  subjected	  to	  an	   in	  vitro	  transwell	  migration	  assay	  (see	  Material	  &	  Methods).	  From	  this	  analysis	  we	  found	  that	  HSPCs	  (i.e.	  LSKs)	  sorted	  from	  diabetic	  mice	  displayed	  a	  significant	  decrease	  in	  the	  ability	  to	  migrate	  a	  SDF-­‐1a	  gradient	  (Figure	  8d).	  	  Since	  we	  observed	  that	  HSPCs	  from	  diabetic	  mice	  had	  impaired	  migration	  towards	  Cxcl12	  without	  a	  change	  in	  the	  expression	  of	  Cxcr4	  –	  the	  cognate	  receptor	  of	  Cxcl12	  –	  we	   inferred	   that	   the	  downstream	   intracellular	   signaling	  of	  Cxcl12-­‐Cxcr4	  binding	  may	  be	  altered	  in	  diabetic	  HSPCs	  compared	  to	  control	  mice.	  Therefore,	  we	  evaluated	  
the	   calcium	   flux	   of	   diabetic	   and	   control	   LSK	   cells	   after	   CXCL12	   exposure.	   No	  difference	  in	  calcium	  flux	  was	  observed	  between	  the	  two	  groups,	  suggesting	  that	  the	  disease	  did	  not	  affect	  CXCR4	  down	  stream	  signaling	  (data	  not	  shown).	  	  Next,	  we	  examined	  the	  ability	  of	  diabetic	  HSPCs	  to	  adhere	  to	  the	  extracellular	  matrix	   component	   fibronectin	   using	   an	   in	   vitro	   adhesion	   assay	   (see	   materials	   &	  Methods).	   Contrary	   to	   impaired	  migration,	  we	   observed	   that	  HSPCs	   isolated	   from	  STZ-­‐treated	  mice	   demonstrated	   increased	   adhesion	   to	   fibronectin	   ex	   vivo	   (Figure	  8e).	  Overall,	   changes	   in	  HSPC	  migratory	  and	  adhesive	  activities	  were	  documented	  that	  could	  contribute	  to	  the	  observed	  phenotype.	  	  To	   determine	   whether	   the	   observed	   changes	   in	   HSPC	   migration,	   adhesion	   and	  antigen	  expression	  profile	  in	  STZ-­‐treated	  mice	  persisted	  in	  a	  normal	  host,	  recipient	  mice	   transplanted	   16	  weeks	   earlier	  with	   CD45.2	   bone	  marrow	   cells	   from	   STZ-­‐	   or	  saline-­‐treated	  mice	  were	  treated	  with	  G-­‐CSF	  (Figure	  9a).	  However,	  no	  difference	  in	  CFU-­‐C	  mobilized	   into	   the	  blood	  was	  observed	  (Figure	  9b).	  Also,	   transplantation	  of	  irradiated	   animals	   with	   mobilized	   blood	   revealed	   that	   the	   contribution	   of	   the	  chimeric	  fractions	  (CD45.1/CD45.2	  ratio)	  was	  equivalent	  in	  the	  two	  groups	  (Figure	  9c,d).	   These	   data	   indicate	   that	   cell	   autonomous	   alterations	   in	   chemotactic	  properties	  were	  not	  persistent	  or	  were	  reverted	  in	  a	  non-­‐diabetic	  host	  suggesting	  a	  role	   for	   the	   bone	   marrow	   (BM)	   microenvironment	   in	   the	   diabetes-­‐induced	  mobilization	   defect.	   Further,	   they	   exclude	   a	   direct,	   durable	   effect	   of	   STZ	   on	  HSPC	  accounting	   for	   their	   mobilization	   abnormality	   and	   argue	   against	   STZ	   damage	   to	  HSPC	  causing	  the	  mobilization	  abnormality.	  Furthermore,	  STZ	  has	  a	  serum	  half-­‐life	  of	   ~15	   minutes	   with	   complete	   clearance	   by	   4	   hours173	   arguing	   against	   durable	  
presence	   of	   STZ	   rather	   than	   its	   effect	   on	   glucose	   control	   as	   the	   basis	   for	   the	  observed	  effect. 	  
From	  these	  data	  we	  postulated	  that	  the	  failed	  HSPC	  mobilization	  in	  diabetic	  animals	  could	  be	  due	  to	  alterations	  in	  the	  bone	  marrow	  (BM)	  microenvironment.	  To	  assess	  whether	  the	  BM	  microenvironment	  was	  sufficient	  to	  induce	  the	  alterations	  in	  HSPC	   numbers	   and	   the	   poor	   G-­‐CSF	   response	   observed	   in	   diabetic	   mice,	   we	  transplanted	   equivalent	   numbers	   of	   wild-­‐type	   CD45.1	   bone	   marrow	   cells	   into	  lethally	   irradiated	   diabetic	   and	   control	   mice	   (Figure	   10a).	   Sixteen	   weeks	   post	  engraftment,	   bone	   marrow	   LSK	   were	   increased	   (Figure	   10b)	   with	   a	   trend	   to	  increased	   LT-­‐HSC	   in	   diabetic	   recipients	   (Figure	   10c-­‐d)	   similar	   to	   the	   results	   we	  obtained	   in	   non-­‐transplanted	   diabetic	   mice.	   Furthermore,	   when	   G-­‐CSF	   was	  administered	   to	   these	   animals,	   the	   number	   of	   circulating	   CFU-­‐C	   was	   lower	   in	  diabetic	   mice	   transplanted	   with	  WT	   cells	   (Figure	   10e).	   Collectively,	   these	   results	  indicate	  that	  HSPC	  exposure	  to	  STZ	  was	  not	  required	  for	  the	  abnormalities	  in	  their	  function.	   Rather,	   persistent	   extrinsic	   signals	   from	   the	   abnormal,	   diabetic	  microenvironment	  or	  a	  rapidly	  reversible	  change	  in	  HSPC	  function	  are	  responsible	  for	  maintaining	  the	  mobilization	  defect	  associated	  with	  diabetes.	  
	  Diabetes	   mediated	   disruption	   of	   the	   osteoblastic	   niche	   contributes	   to	   the	  
mobilization	  defect	  	  
The	  mechanism	  of	   action	   of	  G-­‐CSF	  has	   been	  widely	   studied	   in	  murine	  models.	  The	  CXCL12	  chemokine	  has	  been	  highly	  preserved	  through	  evolution	  and	  in	  fact	  just	  one	   amino	   acid	   distinguishes	   the	   protein	   sequence	   in	   humans	   and	   mice,	   which	  
makes	   the	   murine	   model	   particularly	   useful	   for	   understanding	   human	  haematopoietic	   regulatory	   mechanisms.	   In	   the	   murine	   bone	   marrow,	   CXCR4	   is	  expressed	   by	   the	   HSC	   and	   its	   ligand	   CXCL12	   by	   the	   osteoblasts,	   medullary	  endothelial	  cells	  and	  stromal	  cells174.	  
G-­‐CSF,	  in	  part,	  promotes	  HSPC	  mobilization	  G-­‐CSF	  induce	  stem	  cell	  mobilization	  by	  decreasing	  bone	  marrow	  SDF-­‐1	  and	  up	  regulating	  CXCR-­‐4	  on	  HSPC175-­‐177	  it	  has	  also	  been	  shown	  that	  the	  mobilization	  effect	  lies	  in	  the	  capacity	  of	  G-­‐CSF	  to	  differentially	  modify	   the	  SDF1	  gradient	  (CXCL12)	  between	  the	  bone	  marrow	  and	  the	  peripheral	  blood175,177.	  Some	  studies	  suggest	  that	  suppression	  of	  CXCL-­‐12	  production	  by	  bone	  marrow	   osteoblasts	   is	   critical	   step	   for	   cytokine-­‐induced	   mobilization87,178.	  Administration	   of	   G-­‐CSF	   does	   alter	   osteoblast	   morphology	   along	   with	   an	  oseteoblast-­‐dependent	   down	   regulation	   of	   CXCL-­‐1288.	   However	   osteoblastic	   cells	  are	   heterogeneous	   population	   and	   the	   aforementioned	   studies	   have	   defined	  osteoblastic	  cells	  based	  on	   the	  expression	  of	  non-­‐specific	  surface	  receptor	  profiles	  
178,179	  or	  immunostaining88.	  	  
Osteoblastic	   cells,	   which	   are	   a	   heterogeneous	   mixture	   of	   bone-­‐rleated	  progenitor	   and	   mature	   cells,	   originate	   from	   a	   common	   mesenchymal	   progenitor.	  The	   maturation	   of	   differentiated	   bone	   cells	   from	   mesenchymal	   progenitors,	  commences	  with	  increased	  expression	  of	  the	  transcription	  factors	  runx2	  and	  osterix	  followed	  by	   the	  expression	  of	  more	  mature	  markers	  of	  osteoblastogenesis	  such	  as	  alkaline	   phosphatase,	   collagen	   type	   I	   and	   eventually	   osteocalcin	   180.	  	   This	  differentiation	   is	   gradual	   and	   progresses	   through	   several	   intermediate	   functional	  
stages	   that	   are	   currently	   undetermined	   due	   to	   a	   lack	   of	   well-­‐defined	   surface	  markers.	   	   Despite	   a	   lack	   of	   known	   surface	   markers,	   different	   osteolineage	   cell	  populations	   in	   mice	   can	   be	   distinguished	   by	   the	   expression	   of	   Osterix	   (Osx),	  Osteocalcin	   or	   both.	   To	   determine	   whether	   one	   of	   these	   specific	   subsets	   of	  osteolineage	  cells	  are	  selectively	  altered	  by	  the	  administration	  of	  G-­‐CSF,	  we	  bred	  a	  mouse	   models	   whereby	   osteoblastic	   subsets	   are	   differentially	   labeled	   with	  fluorescent	   proteins	   enabling	   their	   visualization	   and	   perspective	   isolation	   in	   the	  same	   animal.	   To	   visualize	   Osx+	   cells,	   Cre	   recombinase	  was	   expressed	   as	   a	   fusion	  protein	  with	  a	  modified	  estrogen	  receptor	  (ERt)	  allowing	  for	  time	  specific	  activation	  of	   the	   recombinase	   by	   administration	   of	   the	   estrogen	   analogue,	   tamoxifen181.	  Osterix-­‐CreERt2	   (Osx-­‐Cre)	   animals182	   were	   crossed	   with	   Rosa26-­‐loxP-­‐stop-­‐loxP-­‐mcherry	  (Rosa-­‐mCh)	  mice	  so	  that	  osterix	  expressing	  cells	  begin	  to	  express	  mCherry	  at	   the	  time	  of	   tamoxifen	   injection	  and	  then	  their	  progeny	  are	  permanently	   labeled	  for	   the	   remainder	   of	   the	   cell’s	   lifespan.	   Clearance	   of	   tamoxifen	   from	   the	   cells	  mediates	  the	  return	  of	  the	  CreERt	  complex	  to	  the	  inactive	  state,	  thus	  creating	  a	  time	  window	   for	   gene	   modulation	   as	   well	   as	   cell	   population	   tracking183.	   To	   label	   the	  intermediate	   populations	   and	   the	   mature	   populations	   we	   then	   crossed	   Osx-­‐Cre+/Rosa-­‐mCh	   mice	   with	   mice	   expressing	   the	   green	   fluorescent	   protein,	   GFP,	  driven	  by	   the	  osteocalcin	  promoter	   (OC-­‐GFP	  mice).	   In	   this	   triple	   transgenic	  model	  the	  more	  mature	  osteocalcin-­‐producing	  cells	  are	  green,	  the	  most	  immature	  are	  red	  whereas	   the	   intermediate	   population	   that	   differentiated	   after	   the	   injection	   of	  tamoxifen	  are	  double	  positive	  for	  green	  and	  red	  (Figure	  11a).	   	  To	  examine	  how	  G-­‐CSF	   affected	   each	   of	   these	   populations,	   triple	   transgeneic	   mice	   were	   first	  
administered	  Tamoxifen	  to	  activate	  expression	  of	  mCherry	  in	  cells	  expressing	  Osx-­‐CreER.	  Following	  Tamoxifen	  treatment	  mice	  were	  given	  G-­‐CSF	  as	  described	  above.	  From	   this	   analysis,	   we	   observed	   that	   more	   mature	   osteocalcin	   producing	  osteoblasts	  are	  selectively	  inhibited	  and	  both	  ++	  and	  Osx+	  populations	  (p<0.01	  and	  0.001	   respectively)	   are	   significantly	   expanded	   by	   the	   administration	   of	   G-­‐CSF	  (Figure	  11b).	   
	   Based	   on	   these	   results	   we	   wanted	   to	   determine	   whether	  depeletion/inhibition	   of	   osteocalcin-­‐expressing	   osteoblastic	   cells	   is	   a	   functionally	  critical	   step	   in	   the	   ability	   of	   G-­‐CSF	   to	   promote	   HSPC	  mobilization.	   Therefore,	   we	  employed	   a	  mouse	  model	  where	  we	   could	   selectively	   deplete	   osteocalcin	   positive	  cells.	   Specifically,	  mice	  bearing	  a	   transgene	   that	  expresses	  Cre	   recombinase	  under	  the	   regulation	   of	   osteoblast	   specific	   promoter	   osteocalcin	   (OCN-­‐Cre)	  was	   crossed	  with	   mice	   that	   ubiquitously	   express	   a	   flox-­‐stop-­‐flox-­‐diptheria	   toxin	   receptor	  (iDTR)171.	   In	   the	   compound	   transgenic	   animals,	   Cre-­‐mediated	   removal	   of	   a	  transcriptional	   STOP	   cassette	   allows	   for	   constitutive	   expression	  of	  DT	   receptor	   in	  Osteocalcin+	  osetoblastic	  cells.	  Mice	  were	  then	  administered	  diphtheria	  toxin	  (DT)	  –	  wild	   type	   mice	   do	   not	   carry	   the	   DTR	   -­‐	   to	   induce	   efficient	   ablation	   of	   the	   target	  population.	   Mice	   with	   only	   one	   transgene	   were	   used	   as	   controls.	   Diabetes	   was	  induced	   as	   previously	   described	   in	   both	   double	   transgenic	   (Oc-­‐CRE-­‐iDTR)	   and	  controls	   (Oc-­‐CRE	  or	   iDTR).	  After	  deletion	  mice	  were	   treated	  with	  G-­‐CSF	  or	   saline.	  Mobilized	   peripheral	   blood	   was	   transplanted	   in	   lethally	   irradiated	   congenic	  recipients	   along	   with	   support	   cells	   (Figure	   12a).	   Peripheral	   blood	   chimerism	  analysis	   at	  4	  weeks	  was	  used	   to	  define	  progenitor	  mobilization.	  Baseline	   levels	  of	  
LSK	  were	  assessed	  to	  exclude	  a	  potential	  effect	  of	  DT	  administration	  on	  progenitor	  mobilization	  and	  no	  difference	  was	  found	  (data	  not	  shown).	  The	  treatment	  with	  DT	  was	   maintained	   over	   the	   entire	   length	   of	   G-­‐CSF	   administration	   to	   exclude	   the	  possibility	  of	  residual	  osteoblastic	  cell	  function.	  
The	   data	   from	   these	   experiments	   uncovered	   several	   novel	   observations.	  First,	   loss	   of	   osteoblasts	   increased	   the	   number	   of	   progenitors	   in	   the	   blood	  regardless	   of	   G-­‐CSF	   treatment	   indicating	   that	   osteoblasts	   are	   critical	   for	   retaining	  HSPCs	  in	  the	  bone	  marrow	  under	  homeostatic	  conditions.	  Second,	  G-­‐CSF	  mediated-­‐mobilization	   of	   HSPCs	   was	   compromised	   by	   osteoblast	   depletion	   in	   non-­‐diabetic	  control	   mice.	   Third,	   in	   the	   presence	   of	   diabetes,	   osteoblast	   depletion	   completely	  abolished	  any	  residual	  mobilizing	  potential	  of	  G-­‐CSF	  (Figure	  12b).	  	  
However,	   we	   postulated	   that	   additional	   cell	   populations	   contribute	   to	   the	   G-­‐CSF-­‐dependent	   HSPC	   mobilization	   defect	   in	   diabetic	   animals	   given	   that	   osteoblast	  depletion	   without	   diabetes	   did	   not	   have	   the	   same	   degree	   of	   compromise	   as	   the	  setting	  of	  osteoblast	  depletion	  and	  diabetes.	  Moreover,	  it	  is	  known	  that	  several	  cell	  populations	  of	  distinct	  tissue	  origin	  found	  in	  the	  BM	  microenvironment	  contribute	  G-­‐CSF-­‐mediated	   HSPC	   mobilization.	   Therefore,	   we	   hypothesized	   that	   non-­‐osteoblasts	  are	  also	  a	  part	  of	  the	  STZ-­‐induced	  mobilization	  defects	  and	  prompted	  us	  to	   further	   charactherize	   the	   role	   of	   osteoblast	   and	   analyze	   the	   perivascular	  compartment	  in	  diabetic	  animals.	  	  
	   	  Following	  transplantation	  into	  irradiated	  recipients,	  LT-­‐HSCs	  are	  visualized	  near	  osteoblastic	  cells	  and	  sinusoidal	  vessels43.	  LT-­‐HSCs	  are	  retained	  in	  the	  BM	  by	  
interactions	  with	  molecules	  such	  as	  kit	   ligand	  or	  stem	  cell	   factor	  (SCF)	  present	  on	  osteoblastic	  cells184-­‐186	  and	  CXCL12	  on	  a	  variety	  of	  cell	  types,	  including	  perivascular	  cells	  and	  as	  we	  have	  mentioned	  throughout,	  modulating	  CXCL12	  levels	  is	  thought	  to	  be	   a	   requisite	   aspect	   of	   HSPC	   mobilization	   from	   the	   BM	   into	   the	   blood187-­‐189.	  Consequently,	  we	  examined	  microanatomic	  relationships	  between	  osteoblastic	  and	  perivascular	   cells,	   HSPC	   and	   kit	   ligand,	   CXCL12	   levels	   in	   the	   bone	  marrow	   in	   the	  setting	   of	   diabetes.	   	   Mice	   carrying	   a	   transgene	   in	   which	   GFP	   is	   driven	   under	   the	  osteoblast-­‐specific	   Col2.3kb	   promoter190	   or	   the	   Nestin	   promoter191	   (labeling	  mesenchymal	   stem	   cells)	   were	   used	   to	   locate	   these	   cells	   throughout	   the	  microenvironment	  topography.	  	  
	   We	   then	   performed	   high-­‐resolution	   confocal	   microscopy	   and	   two-­‐photon	  video	  imaging	  in	  Nes-­Gfp	  and	  Col2.3-­Gfp	  transgenic	  mice	  after	  injection	  of	  LT-­‐HSCs.	  Briefly,	  calvarial	  BM	  was	  visualized	  following	  the	  injection	  of	  5,000	  dye-­‐labeled	  LT-­‐HSCs.	   The	   total	   number	   of	   HSCs	   and	   measurements	   of	   their	   distance	   relative	   to	  osteoblastic	   cells,	   the	   endosteal	   surface	   and	   Nes-­‐GFP+	   cells	   were	   quantified	   in	  diabetic	  and	  control	  mice.	  The	  first	  observation	  we	  made	  from	  these	  analyses,	  was	  that	   higher	   numbers	   of	   LT-­‐HSCs	   were	   observed	   24hrs	   after	   injection	   in	   diabetic	  mice	  compared	  to	  their	  controls	  (Figure	  13a).	  Clusters	  of	  2,	  3	  or	  more	  DiD	  labeled	  cells	   were	   also	   observed	   at	   higher	   proportion	   in	   diabetic	   mice	   (Figure	   13b).	   To	  assess	   whether	   these	   events	   could	   be	   attributed	   to	   an	   increased	   chemoattractive	  ability	   of	   the	   diabetic	   marrow	   causing	   cell	   accumulation	   or	   to	   induce	   HSPC	  proliferation,	  we	   injected	   a	   1:1	  mixture	   of	   FACS	   sorted	   LT-­‐HSCs	   stained	  with	   the	  lipophilic	  cyanine	  dyes	  DiD	  or	  DiI.	  We	  found	  that	  cells	   in	  clusters	  were	  exclusively	  
stained	  with	   one	   dye,	   consistent	  with	  migration	   and	   proliferation	   of	   a	   single	   cell,	  rather	   than	   co-­‐localization	   of	   multiple	   injected	   HSCs	   (Figure	   13c).	   Further	  evaluation	   was	   conducted	   in	   vitro	   using	   DsRed-­‐stained	   LSK	   CD48-­‐	   cells	   cultured	  over	  a	   layer	  of	  stromal	  cells	  derived	  from	  control	  or	  diabetic	  mice.	  Despite	  several	  days	  of	  normoglycemic	  culture	  conditions	  (5.5	  mM),	  diabetic	  stroma	  still	  promoted	  a	  20%	  increase	  in	  HSPC	  growth	  compared	  to	  normal	  stroma	  (Figure	  13d).	  Together	  with	   the	  higher	   fraction	  of	  cycling	  bone	  marrow	  cells	   found	   in	  diabetic	  mice	  (data	  not	   shown)	   and	   increased	   cell	   number	   detected	   by	   FACS	   and	   two	   photon	   video	  imaging,	  these	  data	  indicate	  that	  the	  diabetic	  stroma	  fosters	  HSPC	  proliferation.	  
	   We	  also	   found	   that	  LT-­‐HSCs	  were	   found	   in	   closer	  proximity	   to	  osteoblastic	  cells	   and	   to	   the	  endosteal	   surface	   in	  diabetic	  mice	  24-­‐48	  hrs	  after	   transplantation	  (Figure	  13d).	  However,	  we	  did	  not	  observe	  any	  difference	  in	  HSPC	  location	  relative	  to	   nestin	   expressing	   perivascular	   cells	   in	   diabetic	   versus	   non-­‐diabetic	   mice.	  Assessment	   of	   mRNA	   levels	   of	   niche-­‐related	   genes	   (CXCL12,	   V-­‐cam1,	   SCF	   and	  angiopoietin-­‐1)	   in	   osteoblastic	   cells	   revealed	   that,	   under	   steady	   state,	   the	  expression	   of	   SCF,	   previously	   associated	   with	   HSPC	   lodgment	   in	   the	   endosteal	  region186,	   was	   ~2-­‐fold	   higher	   in	   diabetic	   mice	   (Figure	   13e),	   consistent	   with	   the	  observed	   closer	   proximity	   of	   HSPCs.	   	   These	   data	   suggest	   that	   the	   diabetic	  microenvironment	  alters	  the	  lodgment	  and	  proliferation	  of	  normal	  HSCs.	  	  
	   Previous	  studies	  have	  shown	  that	  G-­‐CSF-­‐induced	  HSPC	  mobilization	  requires	  down-­‐regulation	   of	   CXCL12	   in	   the	  BM177,192,193.	   In	   steady	   state,	  Nes-­‐GFP+	   cells	   are	  reportedly	   a	   major	   contributor	   of	   CXCL12	   in	   mouse	   bone	   marrow120.	   In	   control	  
mice,	  Cxcl12	  mRNA	   levels	  were	   over	   10-­‐fold	   higher	   in	  Nes-­‐GFP+cells	   compared	   to	  osteoblastic	  cells	  (Figure	  13g).	  Cxcl12	  mRNA	  levels	  in	  Nes-­‐GFP+	  cells	  were	  reduced	  by	  ~2-­‐fold	  in	  diabetic	  animals	  compared	  with	  controls	  (Figure	  14a).	  Exposure	  to	  G-­‐CSF	  had	  minimal	   impact	  on	  Cxcl12	  mRNA	  levels	   in	  Nes-­‐GFP+	  cells	   in	  the	  setting	  of	  diabetes	  while	  Cxcl12	  mRNA	  levels	  were	  efficiently	  down	  regulated	  in	  control	  mice	  (Figure	   14a).	   Thus,	   the	   magnitude	   of	   Cxcl12	   mRNA	   change	   following	   G-­‐CSF	  administration	   was	   dramatically	   lower	   in	   diabetic	   animals	   compared	   to	   controls	  (92%	  versus	  38%).	  This	  was	  the	  consequence	  of	  both	   lower	  baseline	  Cxcl12	  levels	  and	   failure	  of	  G-­‐CSF	  to	   induce	  sufficient	  Cxcl12	  mRNA	  down-­‐regulation.	  The	   lower	  mRNA	   level	   in	  diabetic	  mice	  was	   accompanied	  by	   a	  decrease	   in	  Cxcl12	  protein	   in	  Nes-­‐GFP+	   cells	   by	   flow	   cytometry	   (Figure	   14b	   –	   measurement	   of	   intracellular	  Cxcl12	   is	   described	   in	   Materials	   &	   Methods).	   Despite	   these	   changes	   in	   cell	   type-­‐specific	  mRNA	   levels,	  CXCL12	  protein	   content	   in	  bone	  marrow	  extracellular	   fluids	  did	  not	  change	  (Figure	  14c)	  whereas	  we	  observed	  higher	  CXCL12	  protein	  levels	  in	  the	  peripheral	  blood	  of	  diabetic	  mice	  (p<0.05,	  data	  not	  shown).	  Together,	  these	  data	  suggest	   that	   CXCL12	   expression	   dynamics	   are	   changed	   in	   the	   diabetic	  microenvironment	  in	  a	  cell	  specific	  manner.	  	  
Increased	   sympathetic	   innervation	   and	   impaired	   response	   to	   β-­adrenergic	  
stimulation	  in	  diabetic	  bone	  marrow.	  
Sympathetic	   nervous	   system	   (SNS)	   cells	   also	   participate	   in	   G-­‐CSF-­‐induced	  HSPC	  mobilization.	  Specifically,	  treatment	  with	  G-­‐CSF	  was	  noted	  in	  prior	  studies	  to	  increase	  sympathetic	  activity	  in	  the	  BM,	  leading	  to	  Cxcl12	  mRNA	  downregulation	  in	  
perivascular	   nestin+	  mesenchymal	   stem	   cells	   and	  HSPC	   release88,120.	   Therefore,	   to	  survey	   for	   additional	   potential	   mechanisms	   that	   explain	   the	   compromised	  mobilization	   found	   in	   diabetic	   animals,	   we	   evaluated	   the	   function	   of	   SNS	   cells	   in	  diabetic	  and	  control	  mice.	  To	  do	  so,	  we	  first	  performed	  immunostaining	  for	  tyrosine	  hydroxylase,	   the	   rate-­‐limiting	   enzyme	   in	   catecholamine	   synthesis,	   in	   the	   skull	   of	  diabetic	   and	   control	   mice.	   We	   observed	   that	   catecholaminergic	   nerve	   terminals	  were	   increased	   by	   >2-­‐fold	   in	   the	   calvarial	   bone	  marrow	   of	   diabetic	  mice	   (Figure	  15a-­‐b).	   To	   determine	   whether	   increased	   catecholaminergic	   innervation	   was	  associated	  with	  altered	  sensitization	  of	  β-­‐adrenergic	  receptors	  in	  Nes-­‐GFP+	  cells,	  we	  treated	  diabetic	  and	  control	  Nes-­Gfp	  transgenic	  mice	  with	  the	  β-­‐adrenergic	  receptor	  agonist	   isoproterenol	   and	  measured	   Cxcl12	   mRNA	   levels	   two	   hours	   later	   (Figure	  15c).	  Reduced	  Cxcl12	  mRNA	  levels	  in	  diabetic	  Nes-­‐GFP+	  cells	  were	  confirmed	  under	  steady	   state.	   Further,	   the	   decrease	   in	   Cxcl12	   mRNA	   levels	   after	   isoproterenol	  treatment	   in	   control	   animals	  was	  markedly	  blunted	   in	  diabetic	  mice	   (Figure	  14c).	  	  Similar	  results	  were	  obtained	  from	  unsorted	  bone	  and	  trabecular	  bone	  marrow	  cells	  (Figure	  15d).	  	  
Activation	  of	  the	  β-­‐adrenergic	  receptor	  is	  known	  to	  induce	  c-­‐AMP-­‐dependent	  protein	  kinase	  A	  (PKA)	  phosphorylation	  of	  the	  Threonine	  197	  (T197)	  residue	  in	  the	  catalytic	   subunit	   of	   PKA.	   Therefore,	   we	   assessed	   the	   level	   of	   phospho-­‐PKAT179	   in	  sorted	  Nes-­‐GFP+	  cells	  from	  control	  and	  diabetic	  mice	  both	  under	  baseline	  conditions	  and	   following	   isoproterenol	   administration.	  Western	   analysis	   using	   anti-­‐phospho-­‐T197-­‐PKAα/β revealed	  that	  isoproterenol	  markedly	  increased	  (~2.5	  fold)	  the	  level	  of	   active	  PKA	   in	  non-­‐diabetic	  mice	   (Figure	  14e,f).	  Conversely,	  we	  observed	  higher	  
baseline	   levels	   of	   phospho-­‐PKA	   in	   diabetic	   mice,	   whereas	   isoproterenol	   induced	  only	  minor	  changes	  (Figure	  15e,f).	  	  
β-­‐adrenergic	   signaling	   in	   Nes-­‐GFP+	   cells	   is	   mediated	   by	   binding	   to	   and	  activation	  of	  β3	  adrenoreceptor,	  selectively	  expressed	  on	  nestin	  cells	  and	  absent	  on	  osteoblastic	   cells133.	   Therefore,	  we	   administered	   a	   selective	  β3	   adrenergic	  blocker	  (SR59230A,	   Sigma)	   to	   diabetic	   mice	   and	   compared	   Cxcl12	   level	   to	   that	   of	   saline	  injected	   diabetic	  mice.	   Cxcl12	   levels	   in	   sorted	  Nes-­‐GFP+	  cells	  were	   restored	   by	  β3	  adrenergic	   blockade	   supporting	   the	   model	   of	   sympathetic	   hyperactivity	   causing	  aberrant	  CXCL12	  regulation	  (Figure	  15g).	  These	  results	  are	  consistent	  with	  diabetes	  related	   sympathetic	   nervous	   system	   dysfunction	   perturbing	   the	   molecular	   axis	  governing	  HSPC	  mobilization	  by	  G-­‐CSF.	  	  	  
SNS-­independent	  HSPC	  mobilization	  is	  preserved	  in	  diabetes.	  
All	  of	  our	  evidence	  to	  this	  point	  suggested	  that	   the	   impairment	   in	  stem	  cell	  mobilization	  in	  diabetic	  mice	  observed	  upon	  G-­‐CSF	  challenging	  is	  in	  large	  part	  due	  to	  imbalances	  in	  the	  Cxcl12	  bone	  marrow	  gradient.	  Moreover,	  our	  data	  suggests	  that	  diabetes-­‐related	   damage	   to	   the	   SNS	   disrupts	   the	   ability	   of	   Nestin+	   cells	   to	  appropriately	   down-­‐regulate	   Cxcl12	   in	   response	   to	   G-­‐CSF	   and	   thus	   leading	   to	  inappropriate	  HSPC	  retention.	  Therefore,	  if	  elevated	  concentrations	  of	  Cxcl12	  in	  the	  diabetic	  bone	  marrow	  was	  blocking	  HSPC	  mobilization,	  then	  we	  hypothesized	  that	  blocking	   the	   ability	   of	   Cxcl12	   to	   activate	   Cxcr4	   signaling	   on	  HSPCs	  would	   restore	  normal	   HSPC	  mobilization	   in	   response	   to	   G-­‐CSF.	   To	   address	   this	   notion	   we	   took	  advantage	   of	   the	   FDA-­‐approved	  mobilization	   drug	  AMD3100,	  which	   is	   a	   clinically	  
used	   bicyclam	   antagonist	   that	   reversibly	   blocks	   the	   interaction	   between	   CXCL12	  and	  CXCR482,194-196.	  Both	  diabetic	  and	  non-­‐diabetic	  control	  mice	  were	  injected	  with	  a	   single	   dose	   of	   AMD3100	   (5	   mg/kg).	   One	   hour	   after	   the	   administration	   of	  AMD3100,	   equal	   volumes	   of	   blood	   from	   each	   condition	   were	   separately	  transplanted	  in	  lethally	  irradiated	  non-­‐diabetic	  recipients,	  together	  with	  competitor	  cells.	  Evaluation	  of	  chimerism	  at	  4	  weeks	  showed	  that	  AMD3100	  alone	  was	  able	  to	  mobilize	   an	   equal	   number	   of	  HSPCs	   in	   both	   diabetic	   and	   non-­‐diabetic	  mice	   as	   no	  significant	  differences	  in	  engraftment	  between	  mobilized	  diabetic	  and	  control	  HSPC	  were	  observed	  (Figure	  15h).	  Since	  AMD3100	  alone	  is	  a	  weak	  mobilizer	  compared	  to	  G-­‐CSF197,198	   we	   concomitantly	   administered	   G-­‐CSF	   and	   AMD3100	   together	   and	  found	   that	   co-­‐administration	   of	   AMD3100	  was	   able	   to	   completely	  mitigate	   the	   G-­‐CSF-­‐dependent	   HSPC	  mobilization	   defects	   observed	   in	   diabetic	  mice	   (Figure	   15i).	  These	   data	   are	   consistent	   with	   CXCL12	   modulation	   in	   cells	   of	   the	   marrow	  microenvironment	   being	   the	   primary	   basis	   for	   the	   diabetes-­‐induced	  mobilization	  defect.	  	  
DISCUSSION	  By	   reviewing	   a	   caseload	   of	   patients	   who	   were	   administered	   G-­‐CSF	   to	  mobilize	   HSPCs	   we	   found	   that	   people	   with	   diabetes	   are	   less	   likely	   to	   mobilize	  sufficient	  HSPCs	  or	  in	  other	  words	  diabetics	  are	  more	  likely	  to	  be	  poor	  mobilizers.	  Interestingly,	   from	   the	   same	   review	   of	   patient	   data	   we	   observed	   a	   significant	  inverse	   correlation	   between	   the	   number	   of	   mobilized	   HSPCs	   and	   blood	   glucose	  levels.	   	   In	   order	   to	   gain	   insight	   into	   the	   cellular	   and	  molecular	   abnormalities	   that	  lead	  to	  this	  phenomena,	  we	  utilized	  two	  established	  mouse	  models	  of	  diabetes	  that	  separately	   recapitulate	   type	   I	   and	   type	   II	   diabetes	   and	   both	   displayed	   impaired	  HSPC	   mobilization	   when	   administered	   G-­‐CSF.	   Our	   results	   demonstrate	   that	   this	  mobilization	  defect	   is	  not	   the	  consequence	  of	  reduced	  bone	  marrow	  HSPC	  content	  or	  an	  intrinsic	  HSPC	  defect	  but	  are	  rather	  the	  result	  of	  damage	  to	  non-­‐hematopoietic	  niche	   cells	   that	   lose	   their	   ability	   to	   modulate	   CXCL12	   levels	   in	   the	   BM	  microenvironment.	  Importantly,	  we	  were	  also	  able	  to	  pharmacologically	  reverse	  the	  defect	  with	   the	   FDA-­‐approved	  drug	  AMD3100,	  which	  directly	   inhibit	   the	  CXCL12-­‐CXCR4	  interaction.	  
Our	  findings	  has	  been	  subsequently	  strongly	  substantiated	  by	  a	  prospective	  clinical	  trial	  in	  which	  DM	  and	  control	  subjects	  were	  subjected	  to	  a	  single	  low-­‐dose	  G-­‐CSF	  administration	  to	  study	  stem/progenitor	  cell	  mobilization.	  Compared	  to	  healthy	  subjects,	   patients	   with	   type	   1	   or	   type	   2	   diabetes	   showed	   a	   marked	   inability	   to	  mobilize	  CD34+	  cells	  and	  other	  progenitor	  and	  pro-­‐angiogenic	  phenotypes	  24h	  after	  G-­‐CSF	  199.	  
Taken	  together,	   these	  studies	   indicate	  that	  the	  diabetic	  BM	  fails	  to	  mobilize	  stem/progenitor	  cells	  after	  G-­‐CSF	  and	  tissue	  ischemia,	  a	  pathological	  condition	  now	  deemed	  as	  “mobilopathy”200.	  
This	   mobilopathy	   cannot	   be	   simply	   attributed	   to	   a	   reduction	   in	   the	   number	   of	  intramarrow	  HSPC	  or	  EPC	  that	  can	  be	  mobilized.	  In	  animal	  models	  of	  diabetes,	  the	  number	   of	   BM	   stem	   cells	   was	   found	   to	   be	   decreased,	   unaffected	   or	   even	  increased160,172,	   according	   to	   the	   DM	   model	   type	   and	   duration.	   In	   humans,	   BM	  CD34+	  stem	  cells	  seem	  to	  be	  reduced161,201,202,	  but	  defective	  mobilization	  takes	  place	  before	  baseline	  circulating	  stem	  cell	  levels	  decline199	  
The	  Effects	  of	  Diabetes	  on	  HSCs	  and	  Bone	  Marrow	  Microenvironment	  
We	   documented	   some	   hematopoietic	   cell	   autonomous	   changes	   in	   diabetes	  such	  as	  reduced	  migratory	  ability	  and	   increased	  adherence	   to	  extracellular	  matrix	  components.	   Similar	   findings	   have	   been	   reported	   for	   other	   cell	   types	   in	   diabetic	  settings165,203-­‐205.	  These	  properties	  of	  diabetic	  HSPC	  might	  participate	  in	  the	  altered	  mobilization	   capacity,	   however	   they	   were	   not	   retained	   after	   transplantation	   into	  non-­‐diabetic	   hosts	   suggesting	   that	   the	   phenotype	   may	   be	   rapidly	   reversible.	   We	  therefore	  focused	  on	  whether	  abnormalities	  in	  the	  microenvironment	  were	  present.	  It	  has	  been	  described	  that	  hyperglycemia	   induces	  persistent	  epigenetic	  changes	   in	  stromal	  cells,	  such	  as	  those	  of	  the	  endothelial	  lineage206.	  Correspondingly,	  we	  found	  that	   HSPC	   proliferation	   induced	   by	   diabetic	   bone	   marrow	   stromal	   cells	   was	  maintained	  even	  when	  cultured	  in	  normal	  glucose	  media	  for	  over	  10	  days.	  We	  also	  observed	   that	   diabetes	   derived	   stem	   cells	   gave	   rise	   to	   differentiated	   progenitor	  
skewed	   towards	   the	   myeloid	   phenotype.	   HSCs	   undergo	   dramatic	   changes	   with	  aging.	   An	   increase	   in	   absolute	   numbers	   of	   HSCs	   along	  with	   a	   functional	   deficit	   in	  reconstitution	   potential	   and	   a	   shift	   toward	   production	   of	   myeloid	   cells	   are	   the	  hallmarks	  of	  murine	  hematopoietic	  aging.	  
These	   changes	   have	   been	   attributed	   to	   cell	   intrinsic,	   epigenetic	   and	  microenvironmental	   changes.	   This	   molecular	   profile	   resembles	   the	   elevated	  inflammatory	  state	  previously	  described	  in	  older	  mice	  (“inflamm-­‐aging”)	  	  
In	   our	   model	   these	   observations	   might	   suggest	   that	   diabetes	   could	   be	  responsible	  for	  accelerated	  aging	  of	  the	  stem	  cell	  compartment	  with	  a	  first	  phase	  of	  proliferation	  followed	  eventually	  by	  a	  burnout	  of	  HSPC.	  Moreover,	  we	  showed	  that	  diabetic	   microenvironment	   is	   sufficient	   per	   se	   to	   induce	   early	   proliferation	   of	  transplanted	  wild	  type	  LT-­‐HSC	  and	  this	  phenomenon	  is	  accompanied	  by	  changes	  in	  their	   localization.	   LT-­‐HSCs	   tend	   to	   localize	   closer	   to	   the	   osteoblastic	   cells	   and	   the	  endosteal	   surface	   in	   diabetes	   at	   all	   time	   points	   examined.	   Importantly,	   diabetes	  reduced	  the	  number	  of	  osteoblastic	  cells	  supporting	  the	  notion	  that	  bone	  formation	  is	  impaired	  in	  patients	  affected	  by	  the	  disease.	  By	  selectively	  depleting	  osteoblasts,	  we	   showed	   that	   they	   participate	   in	   the	   residual	   ability	   of	   diabetic	   animals	   to	  mobilize	  to	  G-­‐CSF,	  but	  that	  other	  cell	  types	  also	  contribute.	  	  
Communication	  between	  the	  SNS	  and	  Nestin+	  cells	  is	  disrupted	  in	  Diabetes	  
We	   hypothesized	   and	   found	   that	   nestin+	   mesenchymal	   stem	   cells	   that	   we	  defined	  have	  a	  defect	  in	  CXCL12	  response	  to	  G-­‐CSF	  in	  diabetes.	  Down-­‐regulation	  of	  CXCL12	   is	   a	   critical	   event	   in	   G-­‐CSF-­‐induced	   HSPC	   mobilization88,133,207.	  




Pharmacological	   Targeting	   of	   the	   HSC	   niche	   restores	   HSPC	   mobilization	   in	  
Diabetic	  mice	  	  
Patients	   that	   are	   unable	   to	   sufficiently	   mobilize	   HSPCs	   following	   G-­‐CSF	  treatment	   must	   undergo	   bone	   marrow	   aspiration	   to	   recover	   the	   appropriate	  number	  of	  HSPCs.	  However,	  patients	  that	  are	  autologously	  transplanted	  with	  bone	  marrow-­‐derived	   stem	   cells	   display	   delayed	   engraftment,	   which	   leaves	   patients	  susceptible	  to	  life-­‐threatening	  complications	  such	  as	  sepsis	  and	  bleeding.	  Therefore,	  given	   that	   our	   results	   indicate	   that	   diabetic	   patients	   are	   more	   likely	   to	   be	   poor	  mobilizers,	   it	   is	   of	   significant	   importance	   to	   identify	   pharmacological	  methods	   for	  improving	  HSPC	  mobilization.	  
We	   have	   found	   that	   normal	   HSPC	  mobilization	   can	   be	   restored	   in	   diabetic	  mice	   using	   AMD3100,	   which	   directly	   blocks	   CXCR4-­‐CXCL12	   binding,	   and	   this	  demonstrates	   that	   the	  disease	  does	  not	   affect	   this	   specific	   interaction	  providing	   a	  pathophysiologic	  rationale	  for	  the	  use	  of	  AMD3100	  in	  the	  mobilization	  of	  HSPC	  for	  patients	  with	  diabetes.	  Finally,	  we	  found	  that	  nestin+	  cells	  with	  similar	  morphology	  and	  distribution	   to	   the	  murine	  ones	   are	   also	  present	   in	   the	  human	  bone	  marrow,	  suggesting	   a	   possible	   similar	   role	   in	   human	   disease.	   Although	   the	   short-­‐term	  diabetes	  model	  used	  may	  not	  reflect	  the	  late	  consequences	  of	  diabetes	  encountered	  in	  many	  patients,	  these	  studies	  serve	  as	  a	  guide	  for	  a	  more	  extensive	  evaluation	  of	  diabetic	  patients	  and	  provide	  a	  strong	  rationale	  for	  the	  use	  of	  alternatives	  to	  G-­‐CSF	  for	  stem	  cell	  mobilization	  in	  patients	  with	  diabetes.	  	  
	  
FUTURE	  DIRECTIONS:	  
The	  Possible	  Role	  of	  Inflammation	  and	  Macrophages	  in	  HSPC	  mobilization	  in	  
Diabetes	  	  
Alterations	   in	   BM	   monocyte/macrophage	   cells	   may	   represent	   another	  inflammatory	  drive	  of	  HSPC	  retention	  versus	  mobilization	  in	  DM.	  In	  type	  2	  diabetic	  patients,	   the	   BM/PB	   gradient	   of	   M1	   (inflammatory)	   and	   M2	   (anti-­‐inflammatory)	  monocyte	  subtypes	  suggests	  that	  M2	  cells	  are	  stuck	  in	  the	  BM.	  In	  addition,	  while	  we	  have	   observed	   that	  G-­‐CSF	   fails	   to	  mobilize	  HSPCs	   in	   diabetic	   patients,	   it	   has	   been	  shown	  that	  it	  induces	  an	  efflux	  of	  M2	  from	  the	  diabetic	  BM212.	  We	  have	  preliminary	  data	   in	  mice	   that	   indicate	   that	  diabetes	   induces	  excess	   in	  BM	  macrophages,	  which	  are	  not	  adequately	  suppressed	  by	  G-­‐CSF,	  thus	  also	  possibly	  contributing	  to	  reduced	  HSPC	   mobilization	   (Figure	   16a-­‐b).	   The	   mechanisms	   linking	   hyperglycemia	   to	  augmented	  myelogenesis	  have	  been	  recently	  at	   least	  partially	  clarified	  and	  involve	  the	  excess	  production	  of	  RAGE	  ligands	  by	  neutrophils213.	  
The	  Impact	  of	  the	  Extracellular	  matrix	  in	  HSPC	  mobilization	  and	  Diabetes	  
As	   mentioned	   in	   the	   introduction,	   extracellular	   matrix	   and	   cell	   surface-­‐associated	   macromolecules	   such	   as	   heparan	   sulfate	   Proteoglycans	   are	   the	   core	  structural	   scaffolds	   of	   BM	   niches.	   Ext-­‐1	   is	   a	   glycosyltransferase,	   critical	   for	   the	  biosynthesis	  of	  glucosaminoglycans	  such	  as	  heparan	  sulfate	  (HS)	  and	  therefore,	  HS	  containing	   proteoglycans	   (HSPG)	   such	   as	   syndecans,	   betaglycans	   (type	   III	   TGFb	  receptors),	   glypicans	   and	   some	   isoforms	   of	   the	   hyaluronan	   receptor,	   CD44.	   These	  molecules	   are	   critical	   for	   growth	   factor	   binding	   and	   generating	   extra-­‐cellular	  
gradients	  of	  key	  chemokines	  by	  regulating	   their	   localization	  and	  stability	  and	  as	  a	  result	  affect	  HSPC	  trafficking.	  	  
Interestingly,	   we	   have	   observed	   that	  mice	   that	   lack	   the	   Ext-­‐1	   gene	   specifically	   in	  osteolineage-­‐commmitted	  mesenchymal	  progenitors	  	  -­‐	  Mx1-­‐Cre	  was	  recently	  shown	  to	   delete	   floxed	   alleles	   in	   this	   population	   in	   addition	   to	   hematopoietic	   cells214	   -­‐	  	  restores	  normal	  	  HSPC	  mobilization	  in	  response	  to	  G-­‐CSF	  (Figure	  17).	  do	  not	  exhibit	  hematopoietic	  stem	  cells	  mobilization	  defect	  in	  response	  to	  G-­‐CSF.	  These	  mice	  also	  display	   reduced	   retention	   of	   HSCs	   in	   the	   bone	  marrow	   and	   increased	   amount	   of	  HSPCs	  in	  blood	  and	  spleen	  (Figure	  17a-­‐c).	  
Reasoning	   that	   poor	   retention	   in	   the	   setting	   of	   genetic	   deletion	   of	   EXT1	   could	  indicate	  a	  novel	  means	  of	  enhancing	  stem	  cell	  mobilization,	  we	  tested	  heparin	  and	  protamine	  that	  are	  pharmacologic	  inhibitors	  of	  the	  EXT1	  product	  heparan	  sulfate.	  
Our	   preliminary	   data	   (Figure	   18)	   indicate	   that	   these	   inhibitors	   are	   capable	   of	  inducing	  HSPC	  mobilization.	  They	  do	  so	  in	  a	  manner	  additive	  to	  mobilization	  with	  G-­‐CSF,	  the	  current	  clinical	  standard.	  Further,	  they	  are	  capable	  of	  inducing	  mobilization	  in	   a	   clinically	   relevant	   context	   of	   poor	   mobilization	   in	   response	   to	   G-­‐CSF	  represented	  by	  diabetes.	  	  
Results	   of	   engraftment	   into	   irradiated	   recipients	   of	   the	   blood	   from	   diabetic	  mice	  treated	  with	  heparan	  sulfate	  inhibitor	  heparin	  in	  combination	  with	  G-­‐CSF	  results	  in	  a	  higher	  level	  of	  engraftment	  than	  blood	  from	  the	  animals	  treated	  with	  G-­‐CSF	  alone	  (Figure	  18).	  These	  observations	  prompt	  us	  to	  hypothesize	  that	  Ext-­‐1	  deletion	  could	  slow	   the	   progression	   of	   diabetic	   disease	   by	   improving	   stem	   cell	   mediated	   organ	  
repair.	  As	  mentioned	   previously,	   non	   enzymatic	   glycosylation	   contribute	   to	  many	  pathologic	   processes	   in	   DM.	   Lack	   of	   Ext-­‐1	   mediated	   glycosyl	   transferase	   activity	  could	  reduce	  organ	  damage	  in	  a	  stem	  cell-­‐independent	  manner	  by	  means	  of	  slowing	  the	  progression	  of	  advance	  glycation	  end	  product	  (AGEs)	  formation.	  We	  are	   in	  the	  process	  of	  assessing	  organ	  dysfunction	  in	  kidney	  and	  peripheral	  nerves	  of	  diabetic	  mice	  bearing	  Ext-­‐1	  deletion	  versus	  diabetic	  control	  animal.	  We	  have	  observed	  that	  the	   compromised	   response	   to	   G-­‐CSF	   was	   fully	   corrected	   in	   Type	   I	   diabetic	   mice	  lacking	   Ext1	   expression	   in	   Mx1+	   mesenchymal	   cells	   (Figure	   19a).	   Furthermore,	  combination	   of	   heparin	   with	   G-­‐CSF	   resulted	   in	   normal	   mobilization	   of	   long	   term	  reconstituting	   cells	   in	   diabetic	   animals	   as	   measured	   by	   PB	   competitive	  transplantation	   into	   lethally	   irradiated	   congenic	   mice	   (Figure	   19b).	   These	   data	  demonstrate	   that	   functional	   competitive	   inhibition	   of	   endogenous	   HSPGs	   rescues	  the	   mobilization	   abnormalities	   noted	   in	   animals	   with	   pharmacologically	   induced	  diabetes.	  
These	   data	   would	   provide	   a	   proof	   of	   concept	   that	   developing	   pharmacological	  inhibition	   of	   this	   signaling	   pathway	   is	   a	   legitimate	   strategy	   for	   slowing	   the	  progression	  of	  end	  terminal	  organ	  dysfunction	  in	  diabetes.	  




We	   have	   presented	   our	   data	   indicating	   that	   the	   BM	   is	   a	   major	   target	   of	   diabetic	  damage.	  Diabetes	  compromises	  BM	  architecture	  and	  affects	   its	   function,	  especially	  impairing	   the	  mobilization	  of	   immature	  cells	   into	   the	  bloodstream,	   thus	   impairing	  its	   regenerative	   capacity.	   In	   addition,	   diabetes	   negatively	   affects	   the	   activity	   of	  mobilized	   cells	   by	   altering	   multiple	   components	   of	   the	   HSC	   niche.	   BM	   derived	  progenitors	  are	  involved	  in	  the	  pathophysiology	  and	  natural	  history	  of	  diabetes	  and	  its	   multiorgan	   complications.	   This	   previously	   unrecognized	   function	   of	   the	   BM	   is	  lost	   in	   diabetic	   patients.	   Using	   murine	   selective	   Knockouts	   models	   we	   are	   now	  exploring	   novel	   therapeutic	   strategies	   directed	   to	   restore	   BM	   function	   and	   HSPC	  motility	  possibly	  slowing	  diabetic	  complications.	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Figure	  1:	  	  
	  	  






Figure	   2:	  Schematic	   depicting	   the	  microanatomy	  of	   the	   normal	   hematopoietic	   stem	  













































Figure	   3:	   	   	   Diabetes	   significantly	   alters	   the	   microarchitecture	   of	   the	   Bone	  
Marrow.	   	   Sections	   if	   iliac	   crest	   biopsies	   from	   patient	   without	   (a)	   and	   with	   (b)	  diabetes	  (May	  Grunwald	  Giemsa).	  Scale	  bar	  10	  µm.	  Scale	  bar	  representing	  the	  %	  in	  fractional	  composition	  between	  hemopoietic	  tisse,	  fat	  and	  bone	  in	  diabetic	  and	  non	  diabetic	  individual.	  N=16,	  *p<0.05,	  **p<0.01,	  ***p<0.001.	  	  
Figure	  4	  
(a)	  
2004-­2008:	  Bone	  Marrow	  Transplantation	  Unit-­University	  of	  Parma	  	   Total	   	   	  	   Mobilization	   	   Non	  DM	  	   	   DM	  	  
Number	   98	  (100%)	   	   84	  (85.7%)	   	   14	  (14.3%)	  
Good	  Mobilizers	  >	  20	  CD34+	  
cells/uL	   81	  (82.65%)	   	   79	  (94%)	   	   2	  (14.3%)	  
Poor	  Mobilizers	  <	  20	  CD34+	  
cells/uL	   17	  (17.35%)	   	   5	  (6%)	   	   12	  (85.7%)	  DM:	  Diabetes	  Mellitus	   	   	   	   	   	  Mobilization	  regiment:	  	  chemotherapy	  +	  G-­‐CSF	  	  
(b)	   	   	   	   	   	   (c)	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Figure	  3:	  Diabetes	  reduces	  G-­CSF-­induced	  HSPC	  mobilization	  and	  engraftment	  




	   	  
(b)	  
	  
Figure	   5:	   Diabetes	   reduces	   G-­CSF-­induced	   HSPC	   mobilization.	   Histogram	   plot	  representing	   the	   number	   of	   CFU-­‐C	   per	   100ul	   G-­‐CSF-­‐mobilized	   peripheral	   blood,	   obtained	  from	   db/db	   (a)	   or	   STZ-­‐treated	   (b)	   mice	   with	   different	   glucose	   leves.	   Columns	   represent	  mean	  ±	  s.e.m.,	  n=12,	  *	  p<0.05,	  ***	  p<0.001.	  	  
*CFU-C db/db
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Figure7:	  Characterization	  of	  the	  haemopoietic	  compartment	  in	  the	  BM	  of	  STZ-­treated	  
animals.	  (a)	  Immunophenotypic	  enumeration	  of	  the	  percentages	  of	  LSK	  by	  flow	  cytometry	  in	  the	  BM	  of	  STZ-­‐treated	  or	  control	  mice.	  Data	  are	  mean	  ±	  s.e.m.,	  n=24	  	  ***	  p<0.001.	  (b)	  CFU-­‐C	  numbers	  of	  BM	  cells	  obtained	  from	  STZ-­‐treated	  and	  control	  mice.	  Data	  are	  mean	  ±	  s.e.m.,	  n=6,	   *	   p<0.05.	   (c)	   Percentages	   of	   LT-­‐HSC	   Lin-­‐Sca+cKit+CD150+CD48-­‐	   and	   (d)	   Lin-­‐Sca+cKit+Flk2-­‐CD34-­‐	  in	  the	  BM	  of	  STZ-­‐treated	  or	  control	  mice	  as	  assessed	  by	  flow	  cytometry.	  Data	  are	  mean	  ±	  s.e.m.,	  n=8.	  (e)	  Schematic	  representation	  of	  the	  transplantation	  experiment	  to	  assess	  the	  number/functionality	  of	  BM	  cells	  from	  STZ-­‐induced	  diabetic	  mice.	  (f)	  Donor-­‐derived	   CD45.2+	   cell	   engraftment	   4,	   8,	   12	   and	   16	   weeks	   after	   transplantation	   in	   the	  peripheral	  blood	  of	  secondary	  SJL	  recipient	  mice	   transplanted	  with	  bone	  marrow	  isolated	  
(a)	  
(c)	   (d)	  
(e)	  
(b)	  
from	  STZ-­‐treated	  or	  control	  mice	  and	  mixed	  with	  equal	  amount	  of	  CD45.1	  competitor	  cells.	  Columns	  represent	  mean	  ±	  s.e.m.,	  ***	  p<0.001.	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Figure	   8:	   Diabetes	   alters	   adhesion,	   migration	   and	   surface	   molecules	  
expression	   in	   BM-­‐HSPCs	   (a)	   CFU-­‐C	   relative	   mean	   number	   ±	   s.e.m	   from	   the	  migrated	  FACS-­‐sorted	  LSK	  from	  STZ-­‐treated	  or	  control	  mice	  toward	  the	  SDF-­‐1	  in	  a	  transwell	   assay,	   n=6,	   ***	   p<0.001.	   (b)	   CFU-­‐C	   relative	   mean	   number	   ±	   s.e.m	  representing	  the	  adhesive	  LSK	  content	  within	  4	  hours	   from	  FACS-­‐sorted	  LSK	  from	  control	   or	   STZ-­‐treated	  mice	   plated	   in	   fibronectin	   coated	   24-­‐well	   plates.	   Data	   are	  mean	   number	   relative	   to	   control	   ±	   s.e.m.,	   n=6,	   ***	   p<0.001.	   (c)	  %	   LSK	   and	  mean	  fluorescence	   intensity	   values	   (d)	   of	   two	   different	   experiments	   showing	   the	  expression	  levels	  of	  CXCR4,	  49D	  (α4	  integin),	  49E	  (α5	  integin),	  and	  L-­‐selectin	  	  in	  LSK	  isolated	  from	  STZ-­‐treated	  and	  control	  mice	  (e)	  representative	  FACS	  plots.	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Figure	  9	  
	  
(a)	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  (c)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
CONTROL	   45.1	  baseline	   45.1	  post	  G-­‐CSF	   45.2	  baseline	   45.2	  post	  G-­‐CSF	  #1	   50.8	   54.5	   45.1	   42.7	  #2	   23.9	   22.5	   73	   76	  #3	   33.8	   44.6	   47.6	   52.6	  #4	   38.6	   41.6	   57.7	   56.5	  #5	   65.4	   62.7	   29.3	   30.8	  #6	   61.3	   62.7	   36.4	   34.3	  #7	   41.5	   46.8	   52.4	   50	  #8	   46.8	   37.2	   52.3	   59.9	  	  	   	  	   	  	   	  	   	  	  	   	   	   	   	  






























































(b)	   	   	   	   	   (c)	  
             
(d)	   	   	   	   	   (e) 
           











































































Figure	   11:	   Among	   osteolineage	   cells	   Osteocalcin	   subset	   inhibition	   is	  






































Figure	  11:	  (a)	  Schematic	  representation	  of	  the	  experimental	  design	  used	  to	  selectively	  disrupt	  osteoblastic	  cells	  (see	  methods).	  (b)	  Donor-­‐derived	  CD45.2+	  cell	  engraftment	  4	  weeks	  after	  transplantation	  of	  mobilized	  peripheral	  blood	  in	  lethally	  irradiated	  SJL	  recipients.	  Columns	  represents	  mean±	  s.e.m.,	  n=8	  in	  each	  group,	  
,	  ,	  	  p<0.001	  **,	  ,	  ,	  ##	  p<0.01,	  	  p<	  0.05	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(d)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  





























































































































(f)	   	   	   	   	   (g)	  
	  




Figure	   12:	   Bone	   marrow	   microenvironment	   from	   diabetic	   mice	   augments	  
adhesiveness	   of	   normal	   stem	   cells	   to	   osteoblasts	   and	   increases	   their	  




(a)	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(c)	   	   	   	   	   	   	   	   (d)	  
	  
 
Figure	   14:	   STZ-­‐induced	   diabetic	   mice	   have	   aberrant	   expression	   of	   niche	  
related	  molecules.	  (a)	  Percent	  changes	  in	  the	  expression	  of	  mRNA	  levels	  of	  Cxcl12	  in	  FACS	  sorted	  nestinGFP	  +	  cells	  before	  and	  after	  G-­‐CSF	  treatment	  relative	  to	  control	  nestinGFP+	  cells	  before	  G-­‐CSF	  treatment	  and	  normalised	  to	  GAPDH	  (ΔΔCTmethod).	  Columns	   represent	  mean	   ±	   s.e.m.,	   n=6	   *	   p<0.05	   and	   **p<0.01.	   (B)	   Representative	  FACS	   plots	   and	   graph	   bars	   showing	   percentages	   of	   CXCL12+	   cells	   among	   nestin+	  cells.	  Data	  are	  mean	  ±	  s.e.m.,	  n=6,	  *	  p<0.05.	  (C)	  Concentration	  (pg/ml)	  of	  CXCL12	  in	  BM	  extracellular	  fluid	  from	  control	  and	  STZ-­‐treated	  mice.	  Data	  are	  mean	  number	  ±	  s.e.m.,	  n=6.2.	  	  	  	  
Figure	  15	  
	  
(a)	   	   	   	   	   	   	   	   (b)	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(e)	   	   	   	   	   	   (f)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
(g)	   	   	   	   (h)	   	   	   	   (i)	  


































































































































































Figure	   15:	  PNS	   disautonomy	   mediates	   deregulation	   of	   CXCL12	   gradient.	   (a)	  Representative	  pictures	   from	  whole	  mounting	  of	   calvaria	  of	   controls	   (left	  picture)	  and	  STZ-­‐treated	  mice	  (right	  picture).	  Red	  signal:	  tyrosine	  hydroxilase.	  Scale	  bar:	  50	  mm.	   Nerve	   terminal	   quantification	   in	   terms	   of	   perimeter	   (b)	   in	   calvaria	   of	   STZ-­‐treated	  versus	  controls	  mice	  n=5	  *p<0.05.	  Fold	  changes	  in	  the	  expression	  of	  mRNA	  levels	  of	  CXCL12	  in	  (c)	  nestin+	  cells	  (d)	  bone	  marrow	  from	  control	  and	  STZ-­‐treated	  mice	  in	  baseline	  conditions	  and	  2	  hrs	  after	  injection	  of	  isoproterenol	  (5	  mg/kg	  i.p)	  relative	  to	  control	  cells	  in	  baseline	  and	  normalised	  to	  GAPDH	  (ΔΔCTmethod).	   	  n=6,	  *p<0.5.	  (e)	  Left:	  Western	  blot	  showing	  the	  amount	  of	  phospho-­‐PKA	  (pPKA)	  in	  sorted	  nestin+	   cells	   from	  control	   (+/-­‐	   isoproterenol)	   and	  STZ-­‐treated	   (+/-­‐	   isoproterenol)	  mice.	   Right:	   Histogram	   plot	   showing	   ratio	   in	   pPKA.	   (f)	   Fold	   changes	   in	   the	  expression	  of	  mRNA	  levels	  of	  Cxcl12	  in	  nestin+	  cells	  from	  diabetic	  saline	  treated	  and	  diabetic	   b3	  -­‐blocker	   treated	   (5	   mg/kg/day	   for	   10	   days)	   animals	   relative	   to	   non-­‐diabetic	   controls.	   Data	   are	   normalized	   to	   GAPDH	   (ΔΔCTmethod).	   	   n=6,	   *p<0.5.	  Percentage	   of	   donor	   cell	   engraftment	   4	  weeks	   after	   transplantation	   of	   150	  mL	   of	  mobilized-­‐PB	   from	  STZ-­‐treated	   and	   control	  mice	   (along	  with	  whole	   bone	  marrow	  support	   cells)	   in	   congenic	   lethally	   irradiated	   recipients.	  Mice	  were	  mobilized	  with	  single	  dose	  of	  AMD3100	  (g)	  or	  single	  dose	  of	  AMD3100	  (h)	  at	  the	  end	  of	  the	  G-­‐CSF	  mobilization	  regimen	  (h),	  n=5.	  	  
Figure	  16	  	  
(a)	   	   	   	   	   	   (b)	  
	  	  





Figure	  16: Diabetes	   increases	  the	  amount	  of	  BM	  macrophages. Representative	  FACS	  plots	  of	  gating	  strategy	  used	  to	  evaluate	  the	  percentages	  of	  BM	  macrophages	  




































in	  murine	  BM	  at	  baseline	   in	  normal	   (a)	  or	  diabetic	   (b)	   conditions	  and	  after	  G-­‐CSF	  treatment	  in	  normal	  (c)	  and	  diabetic	  mice	  (d).	  (E)	  Boxplot	  representing	  the	  %	  of	  BM	  macrophages	   in	   the	   aforementioned	   conditions.	   N=3	   per	   group,	   *p<0.5,	   **p<0.01,	  ***p<0.001. 	  
Figure	  17	  
	  
(a)	  	  	  	  	  	  
(b)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  (c)	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	   17:	   EXT1	   influences	   HSPC	   localization.	   	   EXT1	   control	   (WT)	   or	   deleted	  (WT)	  animals	  were	  evaluated	   for	   localization	  of	  WT	  hematopoietic	   cells	  16	  weeks	  following	  transplantation.	  These	  data	  indicate	  that	  EXT1	  in	  the	  microenvironment	  is	  critical	   for	   the	   retention	   of	   HSPC	   and	   that	   EXT1	   deletion	   results	   in	   HSPC	  
Ctrl	  Ext1	  +/+	  Mx1cre+	  	  KO:	  Ext1	  fl/fl	  Mx1cre+	  
mobilization.	   (a)	   Scheme	   of	   experimental	   design.	   (b)	   Bar	   graph	   representing	  hematopoietic	  compartments	  at	  various	  stages	  of	  maturation	  in	  WT	  versus	  Ext1	  KO	  animals	   in	   the	   BM.	   (c)	   Bar	   graph	   representing	   hematopoietic	   compartments	   at	  various	   stages	   of	  maturation	   in	  WT	   versus	   Ext1	  KO	   animals	   in	   the	   spleen.	  N=5,	   *	  p<0.05,	  *	  *p<0.01,	  ***	  p<	  0.001	  	  
Figure	  18:	  	  
	  	  	  	  	  	  
Figure	  18:	  Heparan	  sulfate	  inhibitors	  are	  additive	  to	  G-­‐CSF	  in	  mobilizing	  HSPC.	  Results	   of	   transplantation	   with	   blood	   from	   donor	   undergoing	   mobilization	   with	  either	  G-­‐CSF	  alone	  or	  in	  combination	  with	  the	  heparan	  sulfate	  inhibitors,	  heparin	  or	  protamine	   sulfate.	   Curves	   representing	   recipients’	   engraftment	   at	   different	  timepoints.	  Advantage	   in	  engraftment	   in	  groups	  mobilized	  with	  combination	  of	  G-­‐CSF	  with	   heparin	   or	   protamine	   is	   even	  more	   pronounced	   in	   secondary	   recipients	  (blue	  arrow	  indicates	  secondary	  transplant).	  	  






Figure	  19:	  EXT-­‐1	  inhibition	  restores	  normal	  mobilization	  in	  diabetic	  mice.	  (a)	  Histogram	  plots	  representing	  fold	  changes	  in	  engraftment	  in	  mice	  transplanted	  with	  peripheral	   blood	   collected	   from	   EXT1	   KO	   mice	   with	   and	   without	   diabetes.	   N=8,	  
*p<0.01	   (b)	   Histogram	   plots	   representing	   engraftment	   in	   recipient	   mice	  transplanted	  with	  peripheral	  blood	  from	  mice	  with	  and	  without	  diabetes	  mobilized	  with	  G-­‐CSF	  alone	  or	  with	  combination	  of	  G-­‐CSF	  and	  heparin.	  N=10,	  **p<0.01.	  
	  	  
